# Clinical Intelligence Platform - Solution Outline v0.1

## Current Implementation Scope

**A Multi-Agent AI Platform for Clinical Trial Intelligence**

---

## Executive Summary

The **Clinical Intelligence Platform (CIP)** is an AI-native platform that transforms how clinical teams interact with trial data through a **Persona-Driven Agentic Architecture**. This document describes capabilities across two therapeutic areas: **Total Knee Arthroplasty (TKA)** and **Drug-Eluting Stents (DES)**, with an enterprise-wide vision supporting **six distinct user personas**.

### PoC Scope vs. Future Vision

This document distinguishes between **demonstrable PoC capabilities** and **future enterprise vision**:

| Aspect | PoC Scope (Demonstrable) | Future Vision (Requires Integration) |
|--------|--------------------------|--------------------------------------|
| **Data Sources** | Synthetic clinical trials, public registries, open-access literature | PMS, CRM, eTMF, Financial, Manufacturing QMS |
| **Personas** | 4 with high feasibility (PM, Marketing, Sales, Clinical Ops) | 2 with limited feasibility (Strategy, Quality) |
| **Use Cases** | UC1-UC8 fully demonstrable, UC10-UC12 partially | UC9, UC13-UC20 require enterprise data |
| **Strategic Prompts** | ~38% fully demonstrable | ~62% require enterprise data integration |

**Data Feasibility Legend** (used throughout this document):
- ðŸŸ¢ **PoC Ready**: Demonstrable with synthetic/public data
- ðŸŸ¡ **Partial PoC**: Core functionality demonstrable, some features limited
- ðŸŸ  **Synthetic Possible**: Can generate synthetic data for demo (limited realism)
- ðŸ”´ **Future Vision**: Requires real enterprise data integration

---

## Platform Overview

### Scope

| Dimension | Current State |
|-----------|---------------|
| **Products** | 2 (TKA Medical Device, DES Cardiovascular) |
| **TKA Study** | Public protocol from ClinicalTrials.gov (synthetic patient data) |
| **DES Study** | Public protocol from ClinicalTrials.gov |
| **User Personas** | 6 (Product Manager, Sales, Marketing, Clinical Ops, Strategy, Quality) |
| **Dashboard Modules** | 19 functional modules (1 Foundation + 18 Operational) |
| **AI Agents** | 6 Persona Agents + 13 Specialized Agents |
| **ML/DL Models** | 9 predictive capabilities (4 Tier-1, 2 Tier-2, 3 Tier-3) |
| **Core Use Cases** | 20 implemented (UC1-UC20) |
| **Chat Interface** | Multi-agent conversational queries with RBAC |
| **Intelligent Caching** | Multi-tier caching (LLM responses, API endpoints, data layer) |

### Dual-Product Demonstration

```
+------------------------------------------------------------------+
|                    TWO-PRODUCT DEMONSTRATION                       |
|              (Both based on ClinicalTrials.gov protocols)          |
+------------------------------------------------------------------+
|                                                                    |
|  ORTHOPEDICS                         CARDIOVASCULAR                |
|  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                         â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                |
|  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”            â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”       |
|  â”‚ TKA (Medical Device)â”‚            â”‚ DES (Drug-Eluting   â”‚       |
|  â”‚                     â”‚            â”‚      Stent)         â”‚       |
|  â”‚ ClinicalTrials.gov  â”‚            â”‚ ClinicalTrials.gov  â”‚       |
|  â”‚ Public Protocol     â”‚            â”‚ Public Protocol     â”‚       |
|  â”‚                     â”‚            â”‚                     â”‚       |
|  â”‚ â€¢ Synthetic pts     â”‚            â”‚ â€¢ Public endpoints  â”‚       |
|  â”‚ â€¢ Revision rates    â”‚            â”‚ â€¢ MACE, TLR, TVR    â”‚       |
|  â”‚ â€¢ KSS/OKS scores    â”‚            â”‚ â€¢ Stent thrombosis  â”‚       |
|  â”‚ â€¢ AOANJRR/NJR bench â”‚            â”‚ â€¢ NCDR benchmarks   â”‚       |
|  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜            â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜       |
|            â”‚                                  â”‚                    |
|            â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                    |
|                           â”‚                                        |
|              UNIFIED INTELLIGENCE PLATFORM                         |
|              (Same architecture, different configs)                |
|                                                                    |
+------------------------------------------------------------------+
```

### Architecture

```
+------------------------------------------------------------------+
|                 CLINICAL INTELLIGENCE PLATFORM                     |
+------------------------------------------------------------------+
|                                                                    |
|  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   |
|  â”‚                    FRONTEND (React)                         â”‚   |
|  â”‚  19 Modules â”‚ Chat Interface â”‚ Data Browser â”‚ Simulation    â”‚   |
|  â”‚  Knowledge Builder (Foundation Module)                      â”‚   |
|  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   |
|                              â”‚                                     |
|  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   |
|  â”‚                  AUTHENTICATION & RBAC                      â”‚   |
|  â”‚         SSO â”‚ Role Assignment â”‚ Permission Policies         â”‚   |
|  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   |
|                              â”‚                                     |
|  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   |
|  â”‚                    API LAYER (FastAPI)                      â”‚   |
|  â”‚  UC1-UC20 Endpoints â”‚ Chat â”‚ Protocol â”‚ Simulation â”‚ Browse â”‚   |
|  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   |
|                              â”‚                                     |
|  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   |
|  â”‚                    PERSONA AGENTS (6)                       â”‚   |
|  â”‚  Product Manager â”‚ Sales â”‚ Marketing â”‚ Clinical Ops â”‚       â”‚   |
|  â”‚  Strategy â”‚ Quality                                         â”‚   |
|  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   |
|                              â”‚                                     |
|  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   |
|  â”‚                 SPECIALIZED AGENTS (13)                     â”‚   |
|  â”‚  Knowledge Builder â”‚ Data â”‚ Safety â”‚ Literature â”‚ Registry â”‚   |
|  â”‚  Protocol â”‚ Compliance â”‚ Synthesis â”‚ Code â”‚ Document â”‚      â”‚   |
|  â”‚  Competitive â”‚ Financial â”‚ Sentiment                        â”‚   |
|  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   |
|                              â”‚                                     |
|  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   |
|  â”‚                    DATA LAYER                               â”‚   |
|  â”‚  PostgreSQL â”‚ pgvector â”‚ YAML Config â”‚ Literature PDFs      â”‚   |
|  â”‚  PMS â”‚ CRM â”‚ eTMF â”‚ Financial â”‚ Manufacturing QMS           â”‚   |
|  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   |
|                                                                    |
+------------------------------------------------------------------+
```

---

## Dashboard Modules

### Foundation Module: Product Knowledge Builder

> **This module is the prerequisite for all other platform capabilities.** Before any persona can query the system, a Product Knowledge Base must be configured through a collaborative, AI-assisted onboarding process.

#### Overview

The **Product Knowledge Builder** is a long-running, interactive module where a domain expert collaborates with an AI Agent to construct a comprehensive, validated knowledge corpus for a specific medical device or therapeutic product. This knowledge base then powers all downstream analytics, queries, and document generation.

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    PRODUCT KNOWLEDGE BUILDER                             â”‚
â”‚                    (Foundation for All Modules)                          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                          â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”      â”‚
â”‚  â”‚ PHASE 1         â”‚    â”‚ PHASE 2         â”‚    â”‚ PHASE 3         â”‚      â”‚
â”‚  â”‚ Protocol        â”‚â”€â”€â”€â–¶â”‚ Literature      â”‚â”€â”€â”€â–¶â”‚ Rule            â”‚      â”‚
â”‚  â”‚ Ingestion       â”‚    â”‚ Corpus          â”‚    â”‚ Derivation      â”‚      â”‚
â”‚  â”‚                 â”‚    â”‚ Building        â”‚    â”‚                 â”‚      â”‚
â”‚  â”‚ â€¢ Protocol PDF  â”‚    â”‚ â€¢ PubMed search â”‚    â”‚ â€¢ Eligibility   â”‚      â”‚
â”‚  â”‚ â€¢ USDM 4.0      â”‚    â”‚ â€¢ Registry data â”‚    â”‚ â€¢ Safety rules  â”‚      â”‚
â”‚  â”‚ â€¢ SOA/Endpoints â”‚    â”‚ â€¢ Competitor    â”‚    â”‚ â€¢ Benchmarks    â”‚      â”‚
â”‚  â”‚ â€¢ I/E criteria  â”‚    â”‚   trials        â”‚    â”‚ â€¢ Thresholds    â”‚      â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜      â”‚
â”‚           â”‚                     â”‚                     â”‚                  â”‚
â”‚           â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                  â”‚
â”‚                                 â–¼                                        â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ PHASE 4: Human-in-the-Loop Validation                           â”‚    â”‚
â”‚  â”‚                                                                  â”‚    â”‚
â”‚  â”‚  Domain Expert â—„â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–º AI Agent    â”‚    â”‚
â”‚  â”‚                                                                  â”‚    â”‚
â”‚  â”‚  â€¢ Review derived rules         â€¢ Suggest refinements           â”‚    â”‚
â”‚  â”‚  â€¢ Validate thresholds          â€¢ Identify gaps                 â”‚    â”‚
â”‚  â”‚  â€¢ Approve knowledge items      â€¢ Request clarification         â”‚    â”‚
â”‚  â”‚  â€¢ Add domain expertise         â€¢ Cross-reference sources       â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                 â”‚                                        â”‚
â”‚                                 â–¼                                        â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ PRODUCT KNOWLEDGE BASE (Validated & Versioned)                   â”‚    â”‚
â”‚  â”‚                                                                  â”‚    â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”           â”‚    â”‚
â”‚  â”‚  â”‚ Protocol     â”‚  â”‚ Literature   â”‚  â”‚ Derived      â”‚           â”‚    â”‚
â”‚  â”‚  â”‚ Intelligence â”‚  â”‚ Corpus       â”‚  â”‚ Rules        â”‚           â”‚    â”‚
â”‚  â”‚  â”‚ (structured) â”‚  â”‚ (embeddings) â”‚  â”‚ (validated)  â”‚           â”‚    â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜           â”‚    â”‚
â”‚  â”‚                                                                  â”‚    â”‚
â”‚  â”‚  Version: 1.2.0 | Last Updated: 2024-01-15 | Status: Active     â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

#### Phase 1: Protocol Ingestion

| Component | What It Does | Output |
|-----------|--------------|--------|
| **Protocol Upload** | Accept protocol PDF from ClinicalTrials.gov or internal source | Raw document |
| **LLM Extraction** | Extract structured data using USDM 4.0 schema | Protocol JSON |
| **SOA Parser** | Parse Schedule of Assessments into visit windows | Visit rules |
| **I/E Extractor** | Extract eligibility criteria with OMOP mappings | Eligibility rules |
| **Endpoint Mapper** | Identify primary/secondary endpoints with definitions | Endpoint specifications |

**AI Agent Interaction Example:**
```
Agent: "I've extracted 12 inclusion criteria and 8 exclusion criteria from the protocol.
        Criterion I3 mentions 'adequate bone stock' - this is subjective.
        How should this be operationalized for the study?"

Expert: "Use Paprosky classification. Type I-II is adequate, Type III is exclusion."

Agent: "Understood. I'll add a derived rule:
        'Paprosky Type III bone loss â†’ Exclusion criterion violation'
        Should this also trigger a higher risk score for patients near the boundary?"

Expert: "Yes, Paprosky IIB should flag as elevated risk but not excluded."
```

#### Phase 2: Literature Corpus Building

| Component | What It Does | Output |
|-----------|--------------|--------|
| **Automated PubMed Search** | Query for relevant publications based on product/indication | Publication list |
| **Deep Research Agent** | Multi-round search expanding to related topics, complications, comparators | Extended corpus |
| **Registry Integration** | Ingest benchmark data from AOANJRR, NJR, NCDR | Benchmark parameters |
| **Competitor Analysis** | Identify and ingest published competitor trial data | Comparative dataset |
| **Embedding Generation** | Generate vector embeddings for RAG retrieval | pgvector corpus |

**Deep Research Agent Workflow:**
```
Round 1: Primary search - "total knee arthroplasty outcomes cemented"
         â†’ 245 papers identified, 78 high-relevance

Round 2: Expand to complications - "TKA infection rates", "periprosthetic fracture"
         â†’ 156 additional papers

Round 3: Comparator search - "ATTUNE knee outcomes", "competitor knee survival"
         â†’ 89 comparative papers

Round 4: Risk factor deep-dive - "BMI TKA outcomes", "diabetes knee replacement"
         â†’ 134 risk factor papers

Agent: "I've built a corpus of 502 papers. Key findings:
        - Infection rate benchmark: 1.2% (95% CI: 0.8-1.6%)
        - Revision rate at 5 years: 2.8% (registry average)
        - BMI >35 increases revision risk by HR 1.52

        Should I continue searching for specific sub-populations?"
```

#### Phase 3: Rule Derivation Engine

| Rule Type | Derivation Source | Example |
|-----------|-------------------|---------|
| **Eligibility Rules** | Protocol I/E criteria | `age >= 22 AND age <= 80` |
| **Visit Window Rules** | Protocol SOA | `Visit 3: Day 90 Â± 14 days` |
| **Safety Thresholds** | Literature + Registry | `Infection rate > 2.5% â†’ Signal` |
| **Benchmark Comparators** | Registry data | `NJR 5-year survival: 95.2%` |
| **Risk Factor Weights** | Literature hazard ratios | `Prior revision: HR 2.1` |
| **Deviation Classifiers** | Protocol + GCP | `Missed visit â†’ Minor deviation` |
| **Document Templates** | Regulatory requirements | `DSMB narrative structure` |

**Rule Validation Interface:**
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ DERIVED RULE REVIEW                                              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Rule ID: SR-007                                                  â”‚
â”‚ Type: Safety Signal Threshold                                    â”‚
â”‚ Source: AOANJRR Annual Report 2023, p.47                        â”‚
â”‚                                                                  â”‚
â”‚ Rule: "Flag safety signal if revision rate exceeds 3.2% at      â”‚
â”‚        2 years (upper 95% CI of registry benchmark)"            â”‚
â”‚                                                                  â”‚
â”‚ Confidence: HIGH (derived from N=245,000 procedures)            â”‚
â”‚                                                                  â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚ â”‚ [âœ“ Approve]  [âœŽ Modify]  [âœ— Reject]  [? Discuss with Agent] â”‚ â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                                  â”‚
â”‚ Expert Notes: ____________________________________________       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

#### Phase 4: Continuous Refinement

The knowledge base is not static - it evolves through:

| Trigger | Action | Agent Behavior |
|---------|--------|----------------|
| **New Literature** | Weekly PubMed scan | "3 new publications found. One reports higher infection rates with cement type X. Review?" |
| **Registry Update** | Annual report ingestion | "NJR 2024 data available. Benchmark revision rate changed from 2.8% to 2.6%. Update thresholds?" |
| **Query Gaps** | User questions without answers | "5 users asked about 'metal allergy outcomes' - no literature in corpus. Initiate search?" |
| **Rule Conflicts** | Contradictory evidence found | "New meta-analysis contradicts BMI threshold. HR now 1.3 (was 1.5). Reconcile?" |
| **Validation Feedback** | Expert corrections | "You corrected 3 Paprosky classifications. Should I adjust the extraction model?" |

#### Knowledge Base Artifacts

| Artifact | Format | Usage |
|----------|--------|-------|
| **Protocol Intelligence** | JSON (USDM 4.0) | Eligibility checks, visit windows, endpoint definitions |
| **Literature Corpus** | pgvector embeddings | RAG retrieval for evidence synthesis |
| **Benchmark Parameters** | YAML config | Safety signals, competitive analysis, registry comparison |
| **Derived Rules** | Rule engine JSON | Deviation detection, risk scoring, signal thresholds |
| **Validation Log** | Audit trail | Provenance of all approved rules with expert attribution |
| **Version History** | Git-like versioning | Rollback, comparison, change tracking |

#### API Endpoints

| Endpoint | Method | Purpose |
|----------|--------|---------|
| `/api/v1/knowledge/product/create` | POST | Initialize new product knowledge base |
| `/api/v1/knowledge/protocol/ingest` | POST | Ingest and extract protocol |
| `/api/v1/knowledge/literature/search` | POST | Execute literature corpus building |
| `/api/v1/knowledge/rules/derive` | POST | Generate rules from knowledge base |
| `/api/v1/knowledge/rules/validate` | PUT | Expert validation of derived rules |
| `/api/v1/knowledge/status` | GET | Knowledge base build progress |
| `/api/v1/knowledge/export` | GET | Export knowledge base artifacts |

#### PoC Feasibility: ðŸŸ¢ PoC Ready

This module is **fully demonstrable** with PoC data:
- Protocol ingestion: ClinicalTrials.gov PDFs âœ…
- Literature corpus: PubMed open access âœ…
- Registry benchmarks: Public annual reports âœ…
- Rule derivation: LLM-based extraction âœ…
- Human validation: Interactive workflow âœ…

---

### Implemented Modules (18 Total)

| Module | Purpose | Key Features | Primary Persona | Status | PoC Feasibility |
|--------|---------|--------------|-----------------|--------|-----------------|
| **Executive Dashboard** | Study health overview | Aggregated KPIs, action items, progress tracking | All | âœ… Complete | ðŸŸ¢ PoC Ready |
| **Regulatory Readiness** | Submission assessment | Enrollment, compliance, safety, data completeness scores | Product Manager | âœ… Complete | ðŸŸ¢ PoC Ready |
| **Safety Monitoring** | AE/SAE tracking | Signal detection, registry comparison, patient safety profiles | Product Manager | âœ… Complete | ðŸŸ¢ PoC Ready |
| **Protocol Deviations** | Compliance monitoring | Deviation detection, classification, site trends | Clinical Ops | âœ… Complete | ðŸŸ¢ PoC Ready |
| **Patient Risk** | Risk stratification | Individual risk scores, population distribution, contributing factors | Product Manager | âœ… Complete | ðŸŸ¢ PoC Ready |
| **Protocol Digitization** | Structured protocol data | USDM 4.0 format, SOA, eligibility criteria with OMOP mappings | Clinical Ops | âœ… Complete | ðŸŸ¢ PoC Ready |
| **Simulation Studio** | Outcome forecasting | Monte Carlo simulation, scenario comparison, risk-adjusted projections | Strategy | âœ… Complete | ðŸŸ¢ PoC Ready |
| **Literature Intelligence** | Evidence synthesis | RAG-based search, evidence grading, citation generation | Marketing | âœ… Complete | ðŸŸ¢ PoC Ready |
| **Document Generation** | Automated narratives | DSMB packages, safety summaries, regulatory sections | Marketing | âœ… Complete | ðŸŸ¢ PoC Ready |
| **Competitive Benchmarking** | Trial comparison | Compare endpoints to published competitor trials | Sales | âœ… Complete | ðŸŸ¢ PoC Ready |
| **Data Browser** | Data exploration | Table browsing, filtering, inline editing, export | All | âœ… Complete | ðŸŸ¢ PoC Ready |
| **Data Sources** | Data lineage | Source transparency, provenance tracking | All | âœ… Complete | ðŸŸ¢ PoC Ready |
| **Sales Intelligence** | Battle cards & rebuttals | Competitive evidence, surgeon champions, economic modeling | Sales | Planned | ðŸŸ¡ Partial (literature rebuttals yes, CRM no) |
| **Financial Dashboard** | Study budget tracking | CRO costs, site payments, budget forecasts, change orders | Clinical Ops | Planned | ðŸŸ  Synthetic possible |
| **Complaints Hub** | Complaint triage & MDR | AI categorization, trend detection, vigilance automation | Quality | Planned | ðŸŸ  Synthetic possible |
| **CAPA Dashboard** | Corrective actions | CAPA tracking, effectiveness analysis, root cause linking | Quality | Planned | ðŸŸ  Synthetic possible |
| **Portfolio Health** | Multi-product view | Survivorship trends, sentiment analysis, market positioning | Strategy | Planned | ðŸ”´ Future (requires VoC data) |
| **Content Studio** | Marketing content | SOTA reports, social content, patient materials, claim validation | Marketing | Planned | ðŸŸ¡ Partial (SOTA yes, social limited) |

### Module-to-Use Case Mapping

| Module | Primary Use Cases | User Personas |
|--------|-------------------|---------------|
| Executive Dashboard | UC5: Executive Study Health | All |
| Regulatory Readiness | UC1: Submission Readiness | Product Manager, Clinical Ops |
| Safety Monitoring | UC2: Safety Signal Detection, UC9: Recall Risk | Product Manager, Quality |
| Protocol Deviations | UC3: Deviation Detection | Clinical Ops |
| Patient Risk | UC4: Risk Stratification | Product Manager |
| Protocol Digitization | Protocol Review, UC14: eTMF Audit | Clinical Ops |
| Simulation Studio | Outcome Forecasting, UC15: Portfolio Health | Strategy |
| Literature Intelligence | UC6: Evidence Synthesis, UC12: SOTA Report | Marketing, Sales |
| Document Generation | UC7: Narrative Generation | Marketing, Clinical Ops |
| Competitive Benchmarking | UC8: Trial Comparison, UC10: Battle Cards | Sales |
| Data Browser | Ad-hoc Exploration | All |
| Data Sources | Data Lineage, Provenance | All |
| Sales Intelligence | UC10: Battle Cards, UC11: Economic Value | Sales |
| Financial Dashboard | UC13: Financial Forecast | Clinical Ops |
| Complaints Hub | UC17: Complaints Triage, UC19: Vigilance | Quality |
| CAPA Dashboard | UC18: CAPA Effectiveness | Quality |
| Portfolio Health | UC15: Portfolio Health, UC16: Sentiment | Strategy |
| Content Studio | UC12: SOTA Report | Marketing |

---

## Use Cases (Implemented)

### Core Use Cases (UC1-UC8)

#### UC1: Regulatory Submission Readiness Assessment

**Endpoint:** `/api/v1/uc1/readiness-assessment`

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Enrollment Status | Tracks enrollment vs. target | study_patients |
| Compliance Status | Protocol adherence metrics | Deviation detectors |
| Safety Status | Safety profile completeness | study_adverse_events |
| Data Completeness | Data quality assessment | All study tables |

**Example Query:** *"Are we ready for regulatory submission?"*

#### UC2: Safety Signal Detection & Contextualization

**Endpoint:** `/api/v1/uc2/safety-summary`

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Safety Summary | Study-wide AE/SAE analysis | study_adverse_events |
| Signal Detection | Identifies concerning patterns | AE rates vs. literature |
| Registry Comparison | Benchmarks vs. AOANJRR/NJR (TKA) or NCDR (DES) | registry_benchmarks |
| Patient Profiles | Individual safety narratives | Patient-level data |

**Example Query (TKA):** *"What's our infection rate compared to NJR benchmark?"*
**Example Query (DES):** *"What's our MACE rate compared to NCDR benchmark?"*

#### UC3: Protocol Deviation Detection

**Endpoint:** `/api/v1/uc3/deviations-summary`

| Detector | What It Detects | Severity |
|----------|-----------------|----------|
| Visit Timing | Visits outside protocol windows | Minor/Major |
| Missing Assessment | Required assessments not completed | Major |
| I/E Violation | Eligibility criteria violations | Critical |
| Consent Timing | Consent date issues | Major |
| Missed Visit | Unscheduled patient absences | Minor |

**Example Query:** *"Which sites have the most protocol deviations?"*

#### UC4: Patient Risk Stratification

**Endpoint:** `/api/v1/uc4/population-risk`

| Component | What It Does | Method |
|-----------|--------------|--------|
| Individual Risk | Per-patient risk score | Clinical hazard ratios |
| Population Distribution | Risk tier breakdown | Statistical binning |
| Contributing Factors | Risk factor analysis | Literature-derived HRs |
| High-Risk List | Prioritized surveillance | Ranked by risk score |

**Risk Factors (Literature-Derived):**
- Age >80 years (HR: 1.8)
- BMI >35 (HR: 1.5)
- Diabetes (HR: 1.4)
- Prior revision surgery (HR: 2.1)
- Severe bone loss / Paprosky 3B (HR: 2.5)

**Example Query:** *"Which patients are at highest risk for early revision?"*

#### UC5: Executive Study Health Dashboard

**Endpoint:** `/api/v1/uc5/executive-summary`

| Component | What It Shows |
|-----------|---------------|
| Study Progress | Enrollment curves, completion rates |
| Safety Overview | AE/SAE counts, signal alerts |
| Compliance Summary | Deviation rates by type |
| Action Items | Prioritized intervention list |

**Example Query:** *"Give me the executive summary for the DSMB meeting"*

#### UC6: Literature Intelligence & Evidence Synthesis

**Endpoint:** `/api/v1/uc6/literature-search`

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Semantic Search | RAG-based literature retrieval | pgvector embeddings |
| Evidence Grading | Rates evidence quality (RCT, meta-analysis, cohort) | Publication metadata |
| Citation Generation | Formats references for regulatory docs | Literature database |
| Comparative Analysis | Synthesizes findings across publications | Multi-document RAG |

**Example Query (TKA):** *"Find evidence on cemented vs. cementless fixation in patients >75 years"*
**Example Query (DES):** *"What do meta-analyses say about DAPT duration after DES implantation?"*

#### UC7: Document Generation

**Endpoint:** `/api/v1/uc7/generate-document`

| Document Type | What It Generates | Data Sources |
|---------------|-------------------|--------------|
| DSMB Package | Safety narratives, enrollment summary, action items | UC1-UC5 outputs |
| Safety Summary | AE/SAE narratives with contextualization | study_adverse_events, literature |
| Regulatory Section | Pre-formatted submission sections | Protocol, safety, efficacy data |
| Executive Brief | One-page study status for leadership | All study data |

**Example Query:** *"Generate a safety narrative for the quarterly DSMB report"*

#### UC8: Competitive Benchmarking

**Endpoint:** `/api/v1/uc8/competitive-analysis`

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Trial Identification | Finds comparable published trials | ClinicalTrials.gov, literature |
| Endpoint Comparison | Compares primary/secondary endpoints | Published results |
| Population Matching | Adjusts for demographic differences | Baseline characteristics |
| Gap Analysis | Identifies competitive advantages/risks | Multi-trial synthesis |

**Example Query (TKA):** *"How does our revision rate compare to the ATTUNE knee study?"*
**Example Query (DES):** *"Compare our MACE endpoint to XIENCE trials at 1 year"*

### Extended Use Cases (UC9-UC20)

> **PoC Data Feasibility Note**: Extended use cases vary in demonstrability based on data requirements. Use cases marked ðŸŸ  can use synthetic data for workflow demonstration but lack realistic business value. Use cases marked ðŸ”´ require actual enterprise data integration.

#### UC9: Recall Risk Assessment ðŸ”´

**Endpoint:** `/api/v1/uc9/recall-risk`
**Primary Persona:** Product Manager
**PoC Feasibility:** ðŸ”´ **Future Vision** - Requires real device deficiency reports, complaint data, and manufacturing lot information. Synthetic data would not meaningfully demonstrate recall risk assessment logic.

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Deficiency Trend Analysis | Identifies rising trends in device failures | Device deficiency reports |
| Field Safety Assessment | Determines need for proactive notices | Complaint data, manufacturing lots |
| Regulatory Threshold Check | Compares against MDR/FDA thresholds | Regulatory guidelines |
| Risk Scoring | Calculates recall probability | Multi-factor risk model |

**Example Query:** *"Review the last 12 months of device deficiency reports. Is there a rising trend in specific mechanical failures that warrants a proactive field safety notice?"*

#### UC10: Competitive Battle Cards ðŸŸ¡

**Endpoint:** `/api/v1/uc10/battle-card`
**Primary Persona:** Sales
**PoC Feasibility:** ðŸŸ¡ **Partial PoC** - Literature-based rebuttals and published trial comparisons demonstrable. CRM-based surgeon champion identification requires enterprise data.

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Rebuttal Generation | Creates evidence-based competitive responses | Literature, internal studies |
| Weakness Identification | Cross-references competitor complications | Published literature, study data |
| Champion Identification | Finds surgeons with high success rates | Registry data, CRM |
| Sales Scripting | Generates elevator pitches from evidence | Internal white papers |

**Example Query:** *"Draft a rebuttal for a surgeon currently using a competitor system, specifically highlighting our 88.5% success rate versus their 76.3%."*

#### UC11: Economic Value Modeling ðŸŸ¡

**Endpoint:** `/api/v1/uc11/economic-value`
**Primary Persona:** Sales
**PoC Feasibility:** ðŸŸ¡ **Partial PoC** - Revision cost calculations and ROI projections from survival data demonstrable. Hospital-specific economics require procurement integration.

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Revision Cost Calculation | Calculates avoided revision costs | Survival data, cost models |
| ROI Projection | Projects 5-year cost savings | Survival rates, procedure costs |
| Hospital Economics | Models procurement value proposition | Volume data, pricing |
| Comparative Economics | Compares vs. competitor economics | Market data |

**Example Query:** *"Calculate the predicted 5-year revision cost savings for a hospital if they switch from a competitor with 94% survival to our observed 100% survival."*

#### UC12: SOTA Report Generation ðŸŸ¢

**Endpoint:** `/api/v1/uc12/sota-report`
**Primary Persona:** Marketing
**PoC Feasibility:** ðŸŸ¢ **PoC Ready** - Fully demonstrable using PubMed open-access literature and synthetic CSR data.

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Literature Synthesis | Aggregates recent publications | PubMed, internal CSRs |
| Trend Analysis | Identifies market and clinical trends | Congress abstracts, literature |
| Claim Validation | Validates marketing claims against evidence | Study data, literature |
| Content Generation | Creates SOTA narrative documents | Multi-source synthesis |

**Example Query:** *"Generate a comprehensive 'State-of-the-Art' report for stemless shoulder arthroplasty using internal CSRs and the last 3 years of PubMed publications."*

#### UC13: Financial Forecast ðŸŸ 

**Endpoint:** `/api/v1/uc13/financial-forecast`
**Primary Persona:** Clinical Operations
**PoC Feasibility:** ðŸŸ  **Synthetic Possible** - Can demonstrate workflow with synthetic budget/payment data, but synthetic financials lack realistic business patterns and decision value.

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Budget Analysis | Analyzes CRO change orders and projections | Financial systems |
| Site Payment Calculation | Calculates payments from eCRF completion | Site contracts, eCRF data |
| Site Risk Alert | Identifies budget/enrollment mismatches | Budget data, enrollment |
| Forecast Modeling | Projects remaining study costs | Historical spend, timeline |

**Example Query:** *"Analyze the current CRO change orders and provide a budget estimate for the remaining 24 months of the 5-year follow-up period."*

#### UC14: eTMF Audit ðŸ”´

**Endpoint:** `/api/v1/uc14/etmf-audit`
**Primary Persona:** Clinical Operations
**PoC Feasibility:** ðŸ”´ **Future Vision** - eTMF documents are complex regulatory artifacts with specific legal language, signatures, and audit trails. Synthetic eTMF documents would be meaningless and cannot demonstrate real compliance capabilities.

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Document Completeness | Checks TMF for missing documents | eTMF/ISF |
| License Verification | Flags expired investigator credentials | Regulatory documents |
| Compliance Check | Validates against ICH E6 requirements | GCP guidelines |
| Audit Preparation | Generates audit-ready reports | All trial documentation |

**Example Query:** *"Review the electronic Trial Master File and flag any sites where the Principal Investigator's medical license has expired."*

#### UC15: Portfolio Health Analysis ðŸŸ¡

**Endpoint:** `/api/v1/uc15/portfolio-health`
**Primary Persona:** Strategy
**PoC Feasibility:** ðŸŸ¡ **Partial PoC** - Survivorship trends from public registry data demonstrable. Market positioning and sentiment analysis require CRM/VoC data integration.

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Survivorship Trends | Compares 10-year survival across products | Registry data |
| Market Positioning | Analyzes competitive positioning | Market data, registries |
| R&D Recommendations | Suggests portfolio focus areas | Demographic trends, outcomes |
| Threat Assessment | Evaluates competitive threats | Registry trends, literature |

**Example Query:** *"Compare 10-year survivorship trends of our cemented vs. uncemented portfolios. Should we shift R&D focus based on aging demographic trends?"*

#### UC16: Sentiment Analysis (VoC) ðŸ”´

**Endpoint:** `/api/v1/uc16/sentiment-analysis`
**Primary Persona:** Strategy
**PoC Feasibility:** ðŸ”´ **Future Vision** - Sentiment analysis requires real human feedback (surgeon surveys, IIS data). Synthetic "opinions" would be fabricated sentiment with zero analytical value - meaningless for demonstrating VoC capabilities.

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Surgeon Feedback Analysis | Analyzes IIS and survey feedback | IIS data, surveys |
| Trend Detection | Identifies improving/declining sentiment | Historical surveys |
| Refinement Identification | Extracts requested product improvements | Feedback data |
| Competitive Sentiment | Compares sentiment vs. competitors | Market research |

**Example Query:** *"Perform a sentiment analysis on the last 100 internal surveys regarding instrumentation. Is feedback on 'ease of use' improving or declining compared to 2022?"*

#### UC17: Complaints Triage ðŸŸ 

**Endpoint:** `/api/v1/uc17/complaints-triage`
**Primary Persona:** Quality
**PoC Feasibility:** ðŸŸ  **Synthetic Possible** - Can generate synthetic complaints with failure modes (loosening, infection, pain) to demonstrate triage workflows and categorization. However, synthetic complaints lack realistic business patterns for trend detection.

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| AI Categorization | Auto-categorizes incoming complaints | Complaint reports |
| Trend Detection | Identifies trending failure modes | Complaint data |
| CPM Calculation | Calculates complaints per million | Complaints, sales volume |
| Batch Correlation | Links complaints to manufacturing lots | Complaints, lot data |

**Example Query:** *"Analyze the complaint rate over the last 18 months. Normalize against sales volume (CPM) and identify if the increase in 'liner wear' reports is statistically significant or a byproduct of market growth."*

#### UC18: CAPA Effectiveness ðŸŸ 

**Endpoint:** `/api/v1/uc18/capa-effectiveness`
**Primary Persona:** Quality
**PoC Feasibility:** ðŸŸ  **Synthetic Possible** - Can generate synthetic CAPA records to demonstrate tracking workflows and before/after analysis. However, real CAPA effectiveness requires actual implementation dates and real incident data correlation.

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Before/After Analysis | Compares incident rates pre/post CAPA | CAPA records, complaints |
| Effectiveness Scoring | Quantifies CAPA effectiveness | Incident data |
| Root Cause Linking | Links CAPAs to triggering events | CAPA records, clinical data |
| Trend Monitoring | Tracks CAPA closure and recurrence | CAPA database |

**Example Query:** *"Review the effectiveness of CAPA-2023-004. Compare the incident rate in products manufactured before the fix versus those manufactured after implementation."*

#### UC19: Vigilance Reporting ðŸ”´

**Endpoint:** `/api/v1/uc19/vigilance-report`
**Primary Persona:** Quality
**PoC Feasibility:** ðŸ”´ **Future Vision** - Vigilance reports (MDR, EU MDR Article 87) have specific formatting, coding, and narrative requirements. Synthetic vigilance reports could misrepresent regulatory compliance capabilities and would be meaningless for demonstration.

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Threshold Assessment | Determines reportability per FDA/MDR | Regulatory guidelines |
| Report Drafting | Auto-generates vigilance report drafts | Complaint data |
| RMF Cross-Check | Compares events to Risk Management File | RMF, complaint data |
| Deadline Tracking | Monitors reporting timelines | Regulatory requirements |

**Example Query:** *"A surgeon reported a 'suspected' material failure. Based on FDA 21 CFR 803 and EU MDR Article 87, determine if this event meets the 'Serious Deterioration of Health' threshold and draft the initial Vigilance report."*

#### UC20: PMS Analytics (CPM) ðŸ”´

**Endpoint:** `/api/v1/uc20/pms-analytics`
**Primary Persona:** Quality
**PoC Feasibility:** ðŸ”´ **Future Vision** - CPM calculation requires real sales volume data and complaint data. Geographic clustering and supplier correlation require real manufacturing data. Synthetic data cannot demonstrate meaningful post-market surveillance analytics.

| Component | What It Does | Data Sources |
|-----------|--------------|--------------|
| Geographic Clustering | Identifies regional quality patterns | Complaints, geography |
| Batch-Specific Analysis | Detects lot-specific issues | Complaints, lot data |
| Supplier Correlation | Links complaints to suppliers | Complaints, supplier data |
| Silent Signal Search | Finds unelevated issues in service logs | Service & repair logs |

**Example Query:** *"Cross-reference recent complaints regarding 'baseplate loosening' with manufacturing lot numbers and clean-room environmental logs. Is there a correlation with the batch produced in Q3 2024?"*

---

## Chat Interface

### Capabilities

| Feature | Implementation |
|---------|----------------|
| **Intent Classification** | Routes queries to appropriate agents |
| **Multi-Agent Orchestration** | Coordinates Data, Literature, Registry, Safety agents |
| **Natural Language Queries** | Supports conversational clinical questions |
| **Source Attribution** | Every response includes provenance |
| **Confidence Scoring** | HIGH / MODERATE / LOW / INSUFFICIENT |

### Supported Query Types by Persona

**Product Manager (The "Product Guardian"):**

| Query Type | Example | Primary Agent |
|------------|---------|---------------|
| Safety Correlation | "Identify statistical correlation between component size and complication incidence" | Safety Agent + Data Agent |
| Benchmark Analysis | "Compare 2-year survivorship against bottom 25% in registry" | Registry Agent |
| Recall Risk | "Review device deficiency reports for rising trends" | Safety Agent + Compliance Agent |
| Demographic Impact | "Are revision rates significantly higher in patients with BMI >35?" | Data Agent + Synthesis |
| Regulatory Gap | "List required CERs that are missing or expire within 6 months" | Document Agent |

**Sales (The "Competitive Closer"):**

| Query Type | Example | Primary Agent |
|------------|---------|---------------|
| Rebuttal Generation | "Draft rebuttal highlighting our 88.5% vs competitor's 76.3% success rate" | Competitive Agent + Literature |
| Outcome Visualization | "Extract functional score improvements and generate mobility summary" | Data Agent + Synthesis |
| Competitor Weakness | "Search literature for known competitor complications" | Literature Agent + Competitive |
| Economic Modeling | "Calculate 5-year revision cost savings for switching hospitals" | Financial Agent |
| Champion Identification | "Identify surgeons with high success rates using our implants" | Data Agent (CRM data) |

**Marketing (The "Brand Storyteller"):**

| Query Type | Example | Primary Agent |
|------------|---------|---------------|
| SOTA Generation | "Generate State-of-the-Art report using CSRs and PubMed" | Literature Agent + Synthesis |
| Claim Validation | "Check if 'industry-leading safety' claim is supported by AE rates" | Safety Agent + Literature |
| Patient Narrative | "Identify super-responders and draft de-identified success story" | Data Agent + Document |
| Congress Intelligence | "Scan competitor abstracts for top marketing themes" | Literature Agent + Competitive |
| Channel Content | "Draft LinkedIn posts highlighting 0% device-related AEs" | Document Agent |

**Clinical Operations (The "Compliance & Financial Lead"):**

| Query Type | Example | Primary Agent |
|------------|---------|---------------|
| Financial Forecast | "Analyze CRO change orders and estimate remaining budget" | Financial Agent |
| Site Payments | "Calculate Q4 site payments from eCRF completion" | Financial Agent + Data |
| Site Risk | "Identify sites with <50% enrollment but >80% budget consumed" | Data Agent + Financial |
| MedDRA Coding | "Suggest correct MedDRA codes for 'other' AE entries" | Safety Agent |
| Document Audit | "Flag sites with expired PI medical licenses" | Compliance Agent |

**Strategy (The "Visionary"):**

| Query Type | Example | Primary Agent |
|------------|---------|---------------|
| Sentiment Analysis | "Analyze surgeon feedback for top 3 requested refinements" | Sentiment Agent |
| Portfolio Sustainability | "Compare 10-year survivorship of cemented vs uncemented portfolios" | Registry Agent + Data |
| VoC Trends | "Is feedback on 'ease of use' improving or declining?" | Sentiment Agent |
| Competitive Threat | "Evaluate risk of robotics-assisted systems on manual portfolio" | Competitive Agent + Registry |
| Market Entry | "Simulate evidence requirements for Japanese market entry" | Compliance Agent + Literature |

**Quality Head:**

| Query Type | Example | Primary Agent |
|------------|---------|---------------|
| CPM Analysis | "Normalize complaint rate against sales volume" | Data Agent + Safety |
| Root Cause | "Cross-reference complaints with lot numbers and environmental logs" | Data Agent + Compliance |
| CAPA Effectiveness | "Compare incident rates before vs after CAPA implementation" | Compliance Agent |
| Vigilance Logic | "Determine if event meets 'Serious Deterioration of Health' threshold" | Safety Agent + Compliance |
| RMF Update | "Identify new hazardous situations not in Risk Management File" | Safety Agent |

### Example Interactions

**Product Manager Example:**
```
User: "Compare our 2-year survivorship against the bottom 25% of systems in the registry"

Agent Response:
â”œâ”€â”€ Registry Agent: Retrieves registry benchmark distribution
â”œâ”€â”€ Data Agent: Calculates study survivorship
â”œâ”€â”€ Synthesis Agent: Generates comparative analysis
â””â”€â”€ Response: "Your product shows 98.1% 2-year survivorship, which exceeds
              the bottom 25% threshold of 95.2% by 2.9 percentage points.
              [Source: Study data, Registry Annual Report 2023]"
              Confidence: HIGH
```

**Quality Head Example:**
```
User: "Review CAPA-2023-004 effectiveness for glenosphere locking screw issues"

Agent Response:
â”œâ”€â”€ Compliance Agent: Retrieves CAPA records and implementation date
â”œâ”€â”€ Data Agent: Calculates pre/post incident rates
â”œâ”€â”€ Synthesis Agent: Generates effectiveness analysis
â””â”€â”€ Response: "CAPA-2023-004 shows 78% reduction in incidents.
              Pre-fix rate: 2.3 per 1000 units. Post-fix rate: 0.5 per 1000 units.
              Implementation date: March 2023. N=45,000 units analyzed.
              [Source: CAPA Database, Complaint Records]"
              Confidence: HIGH
```

---

## AI Agents

### Two-Tier Agent Architecture

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                        USER PERSONAS (6)                         â”‚
â”‚  Product Manager â”‚ Sales â”‚ Marketing â”‚ Clinical Ops â”‚           â”‚
â”‚  Strategy â”‚ Quality                                              â”‚
â”‚            (authenticated via SSO/RBAC)                          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                               â”‚
                               â–¼
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                      PERSONA AGENTS (6)                          â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”        â”‚
â”‚  â”‚ Product Mgr   â”‚  â”‚ Sales Agent   â”‚  â”‚ Marketing     â”‚        â”‚
â”‚  â”‚ Agent         â”‚  â”‚               â”‚  â”‚ Agent         â”‚        â”‚
â”‚  â”‚ â€¢ Safety focusâ”‚  â”‚ â€¢ Competitive â”‚  â”‚ â€¢ Content gen â”‚        â”‚
â”‚  â”‚ â€¢ Regulatory  â”‚  â”‚   positioning â”‚  â”‚ â€¢ Claim valid â”‚        â”‚
â”‚  â”‚ â€¢ Recall risk â”‚  â”‚ â€¢ HCP targets â”‚  â”‚ â€¢ SOTA synth  â”‚        â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜        â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”        â”‚
â”‚  â”‚ Clinical Ops  â”‚  â”‚ Strategy      â”‚  â”‚ Quality       â”‚        â”‚
â”‚  â”‚ Agent         â”‚  â”‚ Agent         â”‚  â”‚ Agent         â”‚        â”‚
â”‚  â”‚ â€¢ Financial   â”‚  â”‚ â€¢ Portfolio   â”‚  â”‚ â€¢ Complaints  â”‚        â”‚
â”‚  â”‚ â€¢ Compliance  â”‚  â”‚ â€¢ Sentiment   â”‚  â”‚ â€¢ CAPA/Vigil  â”‚        â”‚
â”‚  â”‚ â€¢ eTMF audit  â”‚  â”‚ â€¢ Market sim  â”‚  â”‚ â€¢ RMF/PMS     â”‚        â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                               â”‚
                               â–¼
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                   SPECIALIZED AGENTS (12)                        â”‚
â”‚  Data â”‚ Safety â”‚ Literature â”‚ Registry â”‚ Protocol â”‚ Compliance  â”‚
â”‚  Synthesis â”‚ Code â”‚ Document â”‚ Competitive â”‚ Financial â”‚        â”‚
â”‚  Sentiment                                                       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
                               â”‚
                               â–¼
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                        DATA LAYER                                â”‚
â”‚  PostgreSQL â”‚ pgvector â”‚ YAML Config â”‚ Literature â”‚ PMS â”‚ CRM   â”‚
â”‚  eTMF â”‚ Financial â”‚ Manufacturing QMS â”‚ Service Logs            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Persona Agents (Goal-Based Orchestration)

| Agent | Persona | Key Capabilities | RBAC Policy |
|-------|---------|------------------|-------------|
| **Product Manager Agent** | Product Manager | Safety/recall focus, regulatory orchestration, benchmark analysis, demographic impact assessment | Full safety data, registry access, regulatory documents |
| **Sales Agent** | Sales | Competitive positioning, surgeon targeting, economic modeling, rebuttal generation | Aggregated clinical data, competitive data, surgeon performance |
| **Marketing Agent** | Marketing | Content generation, claim validation, SOTA synthesis, channel optimization | Published data, evidence summaries, no raw patient data |
| **Clinical Ops Agent** | Clinical Operations | Financial tracking, compliance monitoring, eTMF audit, site management | Full study data, financial data, compliance documents |
| **Strategy Agent** | Strategy | Portfolio analysis, sentiment tracking, market simulation, trend analysis | Cross-portfolio data, market trends, aggregated feedback |
| **Quality Agent** | Quality | Complaints triage, CAPA tracking, vigilance automation, RMF maintenance | All quality data, manufacturing data, complaint records |

**Persona Agent Responsibilities:**
- **Goal-Based Planning**: Decomposes complex user objectives into actionable sub-tasks
- **Query Orchestration**: Routes sub-tasks to appropriate specialized agents
- **Response Synthesis**: Aggregates multi-agent outputs into coherent narratives
- **RBAC Enforcement**: Filters data and actions based on persona permissions
- **Context Management**: Maintains conversation state and user intent

### Specialized Agents (Domain Expertise)

| Agent | Domain | Key Functions |
|-------|--------|---------------|
| **Knowledge Builder Agent** | Product onboarding | Protocol extraction, literature corpus building, rule derivation, human-in-the-loop validation |
| **Data Agent** | Study database | Patient queries, cohort analysis, statistical summaries |
| **Safety Agent** | AE/SAE analysis | Signal detection, severity assessment, safety narratives |
| **Literature Agent** | Evidence search | RAG-based PDF search, evidence grading, citation generation |
| **Registry Agent** | Benchmarking | AOANJRR/NJR (TKA), NCDR (DES), registry comparison |
| **Protocol Agent** | Compliance | Eligibility verification, visit window checks |
| **Compliance Agent** | Deviations | Deviation detection, GCP compliance, eTMF audit |
| **Synthesis Agent** | Narrative generation | Multi-source synthesis, provenance tracking |
| **Code Agent** | Query generation | SQL generation for ad-hoc analysis |
| **Document Agent** | Content generation | DSMB packages, regulatory sections, marketing content |
| **Competitive Agent** | Trial comparison | Endpoint comparison, population matching, gap analysis |
| **Financial Agent** | Budget analysis | CRO costs, site payments, forecast modeling |
| **Sentiment Agent** | VoC analysis | Survey sentiment, feedback trends, NPS analysis |

> **Note**: The Knowledge Builder Agent is unique in that it operates in a long-running, conversational mode with domain experts during the product onboarding phase. It coordinates with Literature Agent, Protocol Agent, and Registry Agent to build the foundational knowledge base.

### RBAC Policy Framework

| Permission | PM | Sales | Mktg | ClinOps | Strategy | Quality |
|------------|:--:|:-----:|:----:|:-------:|:--------:|:-------:|
| Patient-level data | âœ… | âŒ | âŒ | âœ… | âŒ | âœ… |
| Safety narratives | âœ… | âŒ | âœ… | âœ… | âŒ | âœ… |
| Risk scores | âœ… | âŒ | âŒ | âœ… | âœ… | âœ… |
| Financial data | âŒ | âŒ | âŒ | âœ… | âœ… | âŒ |
| Complaints data | âœ… | âŒ | âŒ | âŒ | âŒ | âœ… |
| Manufacturing data | âŒ | âŒ | âŒ | âŒ | âŒ | âœ… |
| Surgeon CRM data | âŒ | âœ… | âŒ | âŒ | âœ… | âŒ |
| Competitive data | âœ… | âœ… | âœ… | âŒ | âœ… | âŒ |
| Document generation | âœ… | âœ… | âœ… | âœ… | âœ… | âœ… |
| Data modifications | âœ… | âŒ | âŒ | âœ… | âŒ | âœ… |
| Simulation runs | âœ… | âŒ | âŒ | âœ… | âœ… | âŒ |

### Agent Capabilities

- **Provenance Tracking**: Every response cites specific data sources
- **Confidence Scoring**: Quantified uncertainty (HIGH/MODERATE/LOW)
- **Async Execution**: Concurrent agent processing for complex queries
- **Error Handling**: Graceful fallbacks with informative messages
- **RBAC Filtering**: Responses automatically filtered by persona permissions

---

## Data Universe

### Data Source Strategy

The platform integrates multiple data sources for comprehensive enterprise intelligence.

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                      DATA SOURCE STRATEGY                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                  â”‚
â”‚   CLINICAL TRIAL DATA                  COMMERCIAL DATA           â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€           â”‚
â”‚   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                 â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”       â”‚
â”‚   â”‚ ClinicalTrials  â”‚                 â”‚ CRM/Surgeon     â”‚       â”‚
â”‚   â”‚ .gov Protocols  â”‚                 â”‚ Database        â”‚       â”‚
â”‚   â”‚ (TKA + DES)     â”‚                 â”‚                 â”‚       â”‚
â”‚   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                 â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜       â”‚
â”‚                                                                  â”‚
â”‚   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                 â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”       â”‚
â”‚   â”‚ Registry Annual â”‚                 â”‚ Sales Volume    â”‚       â”‚
â”‚   â”‚ Reports         â”‚                 â”‚ Data            â”‚       â”‚
â”‚   â”‚ AOANJRR/NJR/NCDRâ”‚                 â”‚                 â”‚       â”‚
â”‚   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                 â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜       â”‚
â”‚                                                                  â”‚
â”‚   QUALITY & COMPLIANCE                 FINANCIAL DATA            â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                 â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€            â”‚
â”‚   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                 â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”       â”‚
â”‚   â”‚ Post-Market     â”‚                 â”‚ CRO Contracts   â”‚       â”‚
â”‚   â”‚ Surveillance    â”‚                 â”‚ Site Payments   â”‚       â”‚
â”‚   â”‚ Complaints/MDR  â”‚                 â”‚ Budget Data     â”‚       â”‚
â”‚   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                 â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜       â”‚
â”‚                                                                  â”‚
â”‚   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                 â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”       â”‚
â”‚   â”‚ Manufacturing   â”‚                 â”‚ eTMF/ISF        â”‚       â”‚
â”‚   â”‚ QMS/Lot Data    â”‚                 â”‚ Regulatory Docs â”‚       â”‚
â”‚   â”‚ CAPA Records    â”‚                 â”‚                 â”‚       â”‚
â”‚   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                 â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜       â”‚
â”‚                                                                  â”‚
â”‚   EVIDENCE & INTELLIGENCE                                        â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                        â”‚
â”‚   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                 â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”       â”‚
â”‚   â”‚ PubMed Open     â”‚                 â”‚ Congress        â”‚       â”‚
â”‚   â”‚ Access Papers   â”‚                 â”‚ Abstracts       â”‚       â”‚
â”‚   â”‚ (literature)    â”‚                 â”‚                 â”‚       â”‚
â”‚   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                 â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜       â”‚
â”‚                                                                  â”‚
â”‚   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                 â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”       â”‚
â”‚   â”‚ IIS/Surgeon     â”‚                 â”‚ Service &       â”‚       â”‚
â”‚   â”‚ Feedback        â”‚                 â”‚ Repair Logs     â”‚       â”‚
â”‚   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                 â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜       â”‚
â”‚                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Data Sources by Category

#### Clinical Trial Data (Current)

| Source | Data Extracted | Usage | Status |
|--------|----------------|-------|--------|
| **ClinicalTrials.gov** | Protocol PDFs for TKA and DES studies | Eligibility criteria, endpoints, SOA, study design | âœ… Active |
| **AOANJRR Annual Report** | TKA revision rates, survival curves by age/gender | Registry benchmarking for orthopedics | âœ… Active |
| **NJR Annual Report** | UK TKA outcomes, infection rates, implant survival | Registry benchmarking for orthopedics | âœ… Active |
| **NCDR CathPCI Registry** | DES MACE rates, stent thrombosis benchmarks | Registry benchmarking for cardiovascular | âœ… Active |
| **PubMed Open Access** | Published RCTs, meta-analyses, cohort studies | Literature RAG, hazard ratios, evidence synthesis | âœ… Active |
| **Published Trial Results** | Competitor trial endpoints | Competitive benchmarking | âœ… Active |

#### Enterprise Data Sources (Planned)

> **Synthetic Data Feasibility Analysis**: The following table includes assessment of whether synthetic data can meaningfully demonstrate each data source's capabilities.

| Source | Data Type | Usage | Primary Persona | Status | Synthetic Feasibility |
|--------|-----------|-------|-----------------|--------|-----------------------|
| **Post-Market Surveillance** | Complaints, MDR reports, vigilance | Quality monitoring, Product Manager alerts | Quality, PM | Planned | ðŸŸ  Complaints: Yes. MDR reports: No (regulatory artifacts) |
| **CRM/Surgeon Database** | Surgeon profiles, implant history, preferences | Sales targeting, champion identification | Sales | Planned | ðŸŸ¡ Basic profiles: Yes. Real surgeon data: No |
| **eTMF/ISF** | Trial documents, site files, regulatory docs | Clinical Ops compliance, audit prep | Clinical Ops | Planned | ðŸ”´ No - complex legal documents with signatures/audit trails |
| **Financial Systems** | CRO contracts, site payments, budgets | Budget tracking, forecasting | Clinical Ops | Planned | ðŸŸ  Workflow demo: Yes. Realistic patterns: No |
| **Manufacturing QMS** | Lot data, CAPA records, environmental logs | Root cause analysis, quality trends | Quality | Planned | ðŸŸ  CAPA records: Yes. Environmental logs: No (sensor data) |
| **Service & Repair Logs** | Technician notes, repairs, silent signals | Early quality detection | Quality | Planned | ðŸ”´ No - requires real operational context |
| **SharePoint/DMS** | Regulatory documents, CERs, technical files | Regulatory gap analysis | Product Manager | Planned | ðŸ”´ No - CERs are formal regulatory submissions |
| **Surgeon Feedback/IIS** | Investigator-initiated studies, surveys | Product refinement, sentiment | Strategy | Planned | ðŸ”´ No - synthetic opinions are meaningless |
| **Congress Abstracts** | Competitor presentations, market themes | Competitive intelligence | Marketing | Planned | ðŸ”´ No - copyrighted content |
| **Sales Volume Data** | Units sold by region/product/lot | CPM calculation, market analysis | Quality, Sales | Planned | ðŸŸ  Basic structure: Yes. Business patterns: No |

### Synthetic Data Generation Strategy

Synthetic data is generated programmatically to create realistic clinical trial datasets that:
- Match protocol-defined eligibility criteria
- Reflect literature-reported event rates
- Follow protocol schedule of assessments
- Exhibit realistic statistical distributions

#### Generation Pipeline

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                 SYNTHETIC DATA GENERATION PIPELINE               â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                  â”‚
â”‚  STEP 1: PROTOCOL EXTRACTION                                     â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ ClinicalTrials.gov PDF                                   â”‚    â”‚
â”‚  â”‚     â†“                                                    â”‚    â”‚
â”‚  â”‚ LLM-based extraction (Gemini)                            â”‚    â”‚
â”‚  â”‚     â†“                                                    â”‚    â”‚
â”‚  â”‚ Structured USDM 4.0 JSON:                                â”‚    â”‚
â”‚  â”‚   â€¢ Eligibility criteria (I/E)                           â”‚    â”‚
â”‚  â”‚   â€¢ Schedule of Assessments (SOA)                        â”‚    â”‚
â”‚  â”‚   â€¢ Primary/Secondary endpoints                          â”‚    â”‚
â”‚  â”‚   â€¢ Visit windows and timing                             â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                              â†“                                   â”‚
â”‚  STEP 2: PARAMETER EXTRACTION FROM LITERATURE                    â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ Published studies + Meta-analyses                        â”‚    â”‚
â”‚  â”‚     â†“                                                    â”‚    â”‚
â”‚  â”‚ Extract statistical parameters:                          â”‚    â”‚
â”‚  â”‚   â€¢ Event rates (AE incidence by type)                   â”‚    â”‚
â”‚  â”‚   â€¢ Demographic distributions (age, BMI, comorbidities)  â”‚    â”‚
â”‚  â”‚   â€¢ Outcome score distributions (mean, SD)               â”‚    â”‚
â”‚  â”‚   â€¢ Hazard ratios for risk factors                       â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                              â†“                                   â”‚
â”‚  STEP 3: COHORT GENERATION                                       â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ Generate patient cohort matching:                        â”‚    â”‚
â”‚  â”‚   â€¢ Protocol eligibility criteria                        â”‚    â”‚
â”‚  â”‚   â€¢ Literature-derived demographic distributions         â”‚    â”‚
â”‚  â”‚   â€¢ Realistic comorbidity profiles                       â”‚    â”‚
â”‚  â”‚   â€¢ Appropriate sample size (e.g., 400 patients)         â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                              â†“                                   â”‚
â”‚  STEP 4: EVENT & OUTCOME GENERATION                              â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ Generate realistic:                                      â”‚    â”‚
â”‚  â”‚   â€¢ Adverse events (type, severity, timing)              â”‚    â”‚
â”‚  â”‚   â€¢ Visit compliance (within protocol windows)           â”‚    â”‚
â”‚  â”‚   â€¢ Functional scores (with expected trajectories)       â”‚    â”‚
â”‚  â”‚   â€¢ Protocol deviations (realistic patterns)             â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                              â†“                                   â”‚
â”‚  STEP 5: VALIDATION                                              â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚
â”‚  â”‚ Validate synthetic data:                                 â”‚    â”‚
â”‚  â”‚   â€¢ All patients meet I/E criteria                       â”‚    â”‚
â”‚  â”‚   â€¢ Event rates within literature confidence intervals   â”‚    â”‚
â”‚  â”‚   â€¢ Distributions pass statistical normality tests       â”‚    â”‚
â”‚  â”‚   â€¢ No impossible combinations (clinical plausibility)   â”‚    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â”‚
â”‚                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

#### TKA Synthetic Data Specification

| Data Type | Records | Generation Method | Validation |
|-----------|---------|-------------------|------------|
| **Patients** | 400 | Demographics from literature distributions; comorbidities from TKA population studies | All meet protocol I/E criteria |
| **Enrollment Timeline** | 400 | Dates following S-curve ramp-up; site staggering; 12-month enrollment period | Realistic enrollment curve shape |
| **Adverse Events** | ~60 | Event types and rates from AOANJRR/NJR; severity distribution from literature | Rates within registry CI |
| **Visits** | ~2,400 | 6 visits per patient per protocol SOA; timing with realistic variance | 95% within protocol windows |
| **Surgeries** | 400 | Procedure details from protocol; implant data randomized | Matches protocol device specs |
| **Functional Scores** | ~1,600 | KSS/OKS at each timepoint; improvement trajectories from literature | Mean/SD matches published data |

#### DES Synthetic Data Specification

| Data Type | Records | Generation Method | Validation |
|-----------|---------|-------------------|------------|
| **Patients** | 300 | Demographics from PCI population; cardiac risk factors from literature | All meet protocol I/E criteria |
| **Enrollment Timeline** | 300 | Dates following S-curve ramp-up; site staggering; 10-month enrollment period | Realistic enrollment curve shape |
| **MACE Events** | ~24 | 8% event rate from literature; time-to-event from survival curves | Rates within NCDR CI |
| **TLR/TVR Events** | ~15 | Rates from published DES trials; correlated with lesion complexity | Matches literature benchmarks |
| **Visits** | ~1,800 | 6 visits per patient; angiographic follow-up per protocol | Per protocol SOA |
| **Lab Values** | ~3,600 | Cardiac biomarkers with realistic ranges and trajectories | Within clinical reference ranges |

### Data Flow Architecture

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                      DATA FLOW ARCHITECTURE                      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                   â”‚
â”‚  â”‚ ClinicalTrials   â”‚    â”‚ Registry Reports â”‚                   â”‚
â”‚  â”‚ .gov Protocols   â”‚    â”‚ (AOANJRR/NJR/    â”‚                   â”‚
â”‚  â”‚ (PDF)            â”‚    â”‚  NCDR)           â”‚                   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                   â”‚
â”‚           â”‚                       â”‚                              â”‚
â”‚           â–¼                       â–¼                              â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                   â”‚
â”‚  â”‚ Protocol         â”‚    â”‚ Benchmark        â”‚                   â”‚
â”‚  â”‚ Extraction       â”‚    â”‚ Extraction       â”‚                   â”‚
â”‚  â”‚ (LLM Pipeline)   â”‚    â”‚ (Manual Curation)â”‚                   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                   â”‚
â”‚           â”‚                       â”‚                              â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”                    â”‚
â”‚  â”‚                                         â”‚                    â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”‚                    â”‚
â”‚  â”‚  â”‚ PMS/Complaintsâ”‚    â”‚ CRM/Surgeon  â”‚  â”‚                    â”‚
â”‚  â”‚  â”‚ Data         â”‚    â”‚ Database     â”‚  â”‚                    â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â”‚                    â”‚
â”‚  â”‚                                         â”‚                    â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”‚                    â”‚
â”‚  â”‚  â”‚ Financial    â”‚    â”‚ eTMF/ISF     â”‚  â”‚                    â”‚
â”‚  â”‚  â”‚ Systems      â”‚    â”‚ Documents    â”‚  â”‚                    â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â”‚                    â”‚
â”‚  â”‚                                         â”‚                    â”‚
â”‚  â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”‚                    â”‚
â”‚  â”‚  â”‚ Manufacturingâ”‚    â”‚ Service &    â”‚  â”‚                    â”‚
â”‚  â”‚  â”‚ QMS          â”‚    â”‚ Repair Logs  â”‚  â”‚                    â”‚
â”‚  â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â”‚                    â”‚
â”‚  â”‚                                         â”‚                    â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                    â”‚
â”‚                        â”‚                                        â”‚
â”‚                        â–¼                                        â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                   â”‚
â”‚  â”‚              YAML CONFIGURATION           â”‚                   â”‚
â”‚  â”‚  protocol.json â”‚ benchmarks.yaml â”‚ hr.yamlâ”‚                   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                   â”‚
â”‚                          â”‚                                       â”‚
â”‚           â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                       â”‚
â”‚           â–¼              â–¼              â–¼                        â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                â”‚
â”‚  â”‚ Synthetic   â”‚ â”‚ Literature  â”‚ â”‚ PostgreSQL  â”‚                â”‚
â”‚  â”‚ Data        â”‚ â”‚ Embeddings  â”‚ â”‚ Database    â”‚                â”‚
â”‚  â”‚ Generator   â”‚ â”‚ (pgvector)  â”‚ â”‚ (study data)â”‚                â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”˜ â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”˜ â””â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”˜                â”‚
â”‚         â”‚               â”‚               â”‚                        â”‚
â”‚         â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                        â”‚
â”‚                         â–¼                                        â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                   â”‚
â”‚  â”‚           SPECIALIZED AGENTS (12)         â”‚                   â”‚
â”‚  â”‚  Data â”‚ Safety â”‚ Literature â”‚ Registry â”‚  â”‚                   â”‚
â”‚  â”‚  Financial â”‚ Sentiment â”‚ Competitive      â”‚                   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                   â”‚
â”‚                         â”‚                                        â”‚
â”‚                         â–¼                                        â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                   â”‚
â”‚  â”‚            PERSONA AGENTS (6)             â”‚                   â”‚
â”‚  â”‚  PM â”‚ Sales â”‚ Marketing â”‚ ClinOps â”‚       â”‚                   â”‚
â”‚  â”‚  Strategy â”‚ Quality                       â”‚                   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                   â”‚
â”‚                         â”‚                                        â”‚
â”‚                         â–¼                                        â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                   â”‚
â”‚  â”‚           API + FRONTEND                  â”‚                   â”‚
â”‚  â”‚  Dashboards â”‚ Chat â”‚ Reports â”‚ Export     â”‚                   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                   â”‚
â”‚                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Database Schema (PostgreSQL)

#### Core Study Tables

| Table | Purpose | Key Columns | Source |
|-------|---------|-------------|--------|
| `study_patients` | Patient demographics | patient_id, age, gender, bmi, comorbidities | Synthetic |
| `study_adverse_events` | AE/SAE records | patient_id, ae_term, severity, is_sae, outcome | Synthetic |
| `study_visits` | Visit compliance | patient_id, visit_type, visit_date, status | Synthetic |
| `study_surgeries` | Procedure data (TKA) | patient_id, surgery_date, implant_type | Synthetic |
| `study_scores` | Functional outcomes | patient_id, score_type, timepoint, value | Synthetic |
| `study_labs` | Lab values (DES) | patient_id, lab_type, value, date | Synthetic |

#### Reference & Intelligence Tables

| Table | Purpose | Key Columns | Source |
|-------|---------|-------------|--------|
| `registry_benchmarks` | Registry comparators | registry_id, metric, value, ci_lower, ci_upper | Public (curated) |
| `literature_publications` | Paper metadata | pub_id, title, year, pmid, evidence_level | Public (PubMed) |
| `literature_embeddings` | RAG vectors | pub_id, chunk_id, embedding (pgvector) | Generated |
| `protocol_rules` | Protocol configuration | rule_type, parameters, thresholds | Extracted |

#### Enterprise Tables (Planned)

| Table | Purpose | Key Columns | Source |
|-------|---------|-------------|--------|
| `complaints` | Complaint records | complaint_id, product, failure_mode, severity, date | PMS |
| `capa_records` | CAPA tracking | capa_id, trigger, status, effectiveness, impl_date | QMS |
| `site_budgets` | Financial data | site_id, budget_total, spent, forecast, variance | Finance |
| `surgeon_profiles` | HCP data | surgeon_id, specialty, volume, products, region | CRM |
| `manufacturing_lots` | Lot tracking | lot_id, product, facility, date, env_conditions | QMS |
| `service_logs` | Repair records | log_id, device_id, technician_notes, issue_type | Service |

---

## ML/DL Predictive Capabilities

The platform incorporates 9 ML/DL predictive models organized in three tiers, designed to work with limited synthetic training data (400 TKA patients + 300 DES patients = 700 total).

### Capability Summary

| Tier | Capability | Model Type | Libraries | Status |
|------|------------|------------|-----------|--------|
| **1** | Enrollment Forecasting | Prophet/ARIMA | prophet, statsmodels | Planned |
| **1** | Survival Analysis | Kaplan-Meier, Cox PH | lifelines, scikit-survival | Planned |
| **1** | Safety Signal Detection | Bayesian SPRT, CUSUM | scipy, pymc | Planned |
| **1** | Risk Stratification (Enhanced) | Ensemble + Calibration | xgboost, lightgbm | Partial |
| **2** | Outcome Trajectory Prediction | LSTM/GRU + LMM fallback | pytorch, statsmodels | Planned |
| **2** | Protocol Deviation Prediction | Gradient Boosting | catboost | Planned |
| **3** | NLP Safety Signal Extraction | LLM (Gemini/Azure OpenAI) | google-generativeai, openai | Planned |
| **3** | Literature Evidence Classification | LLM (Gemini/Azure OpenAI) | google-generativeai, openai | Planned |
| **3** | Functional Recovery Prediction | GMM (simplified) | sklearn.mixture | Planned |

### Tier Definitions

| Tier | Focus | Data Requirements | Implementation Priority |
|------|-------|-------------------|------------------------|
| **Tier 1** | Foundation statistical methods | Works with current dataset | High - enables core analytics |
| **Tier 2** | Advanced predictive models | Benefits from larger datasets | Medium - enhances forecasting |
| **Tier 3** | Deep learning & NLP | Requires transfer learning | Lower - specialized use cases |

### Tier 1: Foundation Capabilities

#### 1.1 Enrollment Forecasting

**Models:** Prophet + ARIMA ensemble

| Component | Details |
|-----------|---------|
| **Features** | Historical enrollment rates, site activation dates, screening-to-enrollment ratios, seasonal patterns |
| **Output** | Enrollment timeline with confidence intervals, site-level forecasts, completion probability |
| **Integration** | Enhances `simulation_service.py` with time-series enrollment forecasting |
| **Applicability** | Both (TKA and DES) |

**Note:** Demonstrates technical integration with synthetic enrollment curves. Production deployment requires real historical enrollment data for accurate forecasting. Synthetic patterns are algorithmically generated and may not reflect real-world enrollment dynamics (COVID disruptions, site ramp-up variability, seasonal effects).

#### 1.2 Survival Analysis

**Models:** Kaplan-Meier, Cox Proportional Hazards, Weibull AFT

| Component | Details |
|-----------|---------|
| **Features** | Time-to-event (TKA: revision; DES: MACE, TLR, TVR), patient covariates (age, BMI, comorbidities), device/procedural characteristics |
| **Output** | Survival curves, hazard ratios with CI, benchmark comparisons (AOANJRR/NJR for TKA, NCDR for DES) |
| **Integration** | Provides statistical foundation for risk stratification and regulatory analysis |
| **Applicability** | Both (TKA and DES) |

#### 1.3 Safety Signal Detection

**Models:** Bayesian Sequential Probability Ratio Test (SPRT), CUSUM charts

| Component | Details |
|-----------|---------|
| **Features** | AE counts by type, expected event rates from literature, temporal patterns |
| **Output** | Signal scores, early warning alerts, disproportionality metrics (PRR, ROR) |
| **Integration** | Enhances `safety_service.py` with statistical signal detection |
| **Applicability** | Both (TKA and DES) |

**Note:** Statistical power limited with ~100 total events. Signals require clinical validation before action.

#### 1.4 Enhanced Risk Stratification

**Models:** Ensemble (XGBoost + LightGBM + Logistic Regression) with SHAP explanations

| Component | Details |
|-----------|---------|
| **Features** | 50+ covariates (demographics, functional scores, comorbidities, surgical/procedural factors) |
| **Output** | Calibrated risk probabilities, feature importance rankings, individual explanations |
| **Integration** | Enhances `risk_service.py` with ensemble predictions and model interpretability |
| **Applicability** | Both (TKA and DES) |

### Tier 2: Advanced Capabilities

#### 2.1 Outcome Trajectory Prediction

**Model:** LSTM/GRU neural network with linear mixed models (LMM) fallback

| Component | Details |
|-----------|---------|
| **Features** | Longitudinal functional scores (KSS/OKS for TKA, Seattle Angina Questionnaire for DES), visit patterns, interventions, baseline characteristics |
| **Output** | Predicted score trajectories at future timepoints, trajectory cluster assignments, deviation alerts |
| **Integration** | Enhances `simulation_service.py` with patient-specific outcome forecasting |
| **Applicability** | Both (TKA and DES) |

**Note:** Falls back to linear mixed models if LSTM performance inadequate due to sample size.

#### 2.2 Protocol Deviation Prediction

**Model:** CatBoost gradient boosting

| Component | Details |
|-----------|---------|
| **Features** | Site history, patient complexity, scheduling patterns, coordinator workload |
| **Output** | Per-patient deviation probability, deviation type predictions, risk flags |
| **Integration** | Enhances `deviation_service.py` with predictive alerts for proactive intervention |
| **Applicability** | Both (TKA and DES) |

**Note:** Uses SMOTE oversampling or class weights to handle expected 90%+ non-deviation rate.

### Tier 3: Deep Learning & NLP Capabilities

#### 3.1 NLP Safety Signal Extraction

**Model:** LLM-based extraction (Gemini/Azure OpenAI)

| Component | Details |
|-----------|---------|
| **Features** | Free-text adverse event narratives, clinical notes |
| **Output** | Standardized MedDRA terms, severity classification, causality assessment |
| **Method** | Zero-shot/few-shot prompting with structured output schemas |
| **Integration** | Enhances `safety_service.py` with automated AE coding |
| **Applicability** | Both (TKA and DES) |

#### 3.2 Literature Evidence Classification

**Model:** LLM-based classification (Gemini/Azure OpenAI)

| Component | Details |
|-----------|---------|
| **Features** | Publication abstracts, full-text sections, study design metadata |
| **Output** | Evidence level (I-IV per Oxford CEBM), quality scores, relevance ranking |
| **Method** | Structured prompts with Oxford CEBM criteria; chain-of-thought reasoning |
| **Integration** | Enhances `literature_service.py` with automated evidence grading |
| **Applicability** | Both (TKA and DES) |

#### 3.3 Functional Recovery Prediction

**Model:** Gaussian Mixture Models (simplified)

| Component | Details |
|-----------|---------|
| **Features** | Subgroup characteristics, early functional scores, baseline biomarkers, surgical/procedural factors |
| **Output** | Recovery phenotype classification (2-3 phenotypes: optimal/suboptimal; TKA: KSS/OKS trajectory; DES: angina relief), trajectory predictions |
| **Integration** | Supports patient counseling on expected recovery and identifies candidates for enhanced rehabilitation |
| **Applicability** | Both (TKA and DES) |

**Note:** Limited to 2-3 recovery phenotypes (optimal/suboptimal) rather than fine-grained clustering due to sample size constraints.

### Data Strategy for Synthetic Training Data

Given the synthetic training data (400 TKA patients + 300 DES patients = 700 total), the platform employs several strategies to maximize model performance:

| Strategy | Application | Benefit |
|----------|-------------|---------|
| **Transfer Learning** | Prophet pre-trained seasonality; LLM zero-shot for NLP | Leverage pre-trained knowledge |
| **LLM Zero-Shot/Few-Shot** | Gemini/Azure OpenAI for NLP tasks | Leverage pre-trained knowledge without fine-tuning |
| **Cross-Study Learning** | Combined TKA + DES datasets for shared features (demographics, comorbidities, visit compliance) | Increase effective sample size for common patterns |
| **Bayesian Priors** | Literature-derived informative priors for all models | Incorporate external knowledge to stabilize estimates |
| **Cross-Validation** | Stratified k-fold (k=5) with careful train/test splits | Maximize use of data for validation |
| **Ensemble Methods** | Combine multiple weak learners | Reduce variance and improve generalization |
| **Strong Regularization** | L1/L2 penalties, dropout, early stopping | Prevent overfitting on synthetic datasets |

**Recommended Data Split (per therapeutic area):**
- Training: 70% (~490 patients total: 280 TKA + 210 DES)
- Validation: 15% (~105 patients total: 60 TKA + 45 DES)
- Test: 15% (~105 patients total: 60 TKA + 45 DES)

### Model Validation Requirements

| Requirement | Metric | Target |
|-------------|--------|--------|
| **Discrimination** | AUC-ROC | â‰¥0.70 for clinical utility |
| **Calibration** | Hosmer-Lemeshow | p > 0.05 |
| **Survival Models** | C-index (Harrell's) | â‰¥0.65 |
| **Trajectory Models** | MAE (Mean Absolute Error) | Model-specific |
| **Classification (NLP)** | F1-score (macro) | â‰¥0.75 |
| **External Validation** | Independent test set | Required before deployment |
| **Clinical Review** | SME sign-off | Required for each model |
| **Monitoring** | Drift detection | Continuous post-deployment |

### Service Integration Points

| Existing Service | ML Enhancement |
|------------------|----------------|
| `risk_service.py` | + Enhanced ensemble models + SHAP explanations |
| `safety_service.py` | + Bayesian signal detection + LLM-based AE extraction |
| `simulation_service.py` | + Prophet enrollment forecasting + LSTM outcome trajectory |
| `deviation_service.py` | + Protocol deviation predictive alerts |
| `literature_service.py` | + LLM-based evidence classification |

---

## Technology Stack

### Backend

| Component | Technology |
|-----------|------------|
| **Framework** | FastAPI (Python 3.10+) |
| **Database** | PostgreSQL + pgvector |
| **ORM** | SQLAlchemy |
| **Data Processing** | pandas, numpy |
| **Validation** | Pydantic |

### ML/DL Libraries

| Category | Libraries |
|----------|-----------|
| **Time Series** | prophet, statsmodels (ARIMA, linear mixed models) |
| **Survival Analysis** | lifelines, scikit-survival |
| **Statistical** | scipy, pymc (Bayesian) |
| **Gradient Boosting** | xgboost, lightgbm, catboost |
| **Deep Learning** | pytorch (LSTM/GRU) |
| **LLM APIs** | google-generativeai (Gemini), openai (Azure OpenAI) |
| **Mixture Models** | sklearn.mixture (GMM) |
| **Explainability** | shap |

### Frontend

| Component | Technology |
|-----------|------------|
| **Framework** | React 18 + TypeScript |
| **Build** | Vite |
| **UI Components** | Shadcn/ui |
| **Charts** | Recharts |

### LLM Integration

| Provider | Usage |
|----------|-------|
| **Google Gemini** | Primary LLM for reasoning |
| **Azure OpenAI** | Fallback / consensus |

### Configuration

```
GEMINI_API_KEY          # Google API key
AZURE_OPENAI_API_KEY    # Azure API key
AZURE_OPENAI_ENDPOINT   # Azure endpoint
DATABASE_URL            # PostgreSQL connection
```

### Intelligent Caching

Multi-tier caching architecture optimizes performance and reduces API costs across all platform layers.

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                   INTELLIGENT CACHING ARCHITECTURE               â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                  â”‚
â”‚  TIER 1: LLM RESPONSE CACHE                                     â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                       â”‚
â”‚  â€¢ Semantic query hashing for similar prompt detection           â”‚
â”‚  â€¢ TTL-based expiration (configurable per query type)            â”‚
â”‚  â€¢ Cost reduction for repeated LLM API calls                     â”‚
â”‚                                                                  â”‚
â”‚  TIER 2: API ENDPOINT CACHE                                     â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                       â”‚
â”‚  â€¢ Async warmup on application startup                           â”‚
â”‚  â€¢ Background refresh (15-minute default interval)               â”‚
â”‚  â€¢ Endpoint-specific TTL configuration                           â”‚
â”‚                                                                  â”‚
â”‚  TIER 3: DATA LAYER CACHE                                       â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                       â”‚
â”‚  â€¢ Query result caching for expensive computations               â”‚
â”‚  â€¢ Invalidation on data updates                                  â”‚
â”‚  â€¢ Memory-efficient LRU eviction policy                          â”‚
â”‚                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

| Cache Tier | Target | Strategy | TTL | Benefit |
|------------|--------|----------|-----|---------|
| **LLM Response** | Gemini/Azure OpenAI calls | Semantic hash matching | 1-24 hours | 60-80% API cost reduction |
| **API Endpoint** | UC1-UC20 endpoints | Async warmup + refresh | 15 minutes | Sub-second response times |
| **Data Layer** | PostgreSQL queries | LRU with invalidation | Query-dependent | Reduced DB load |

**Cache Invalidation Triggers:**
- Manual refresh via API endpoint
- Data modification events (patient updates, new AEs)
- TTL expiration with background refresh
- Memory pressure (LRU eviction)

---

## Limitations & Guardrails

### Current Limitations

| Limitation | Status | Mitigation |
|------------|--------|------------|
| **LLM Hallucination** | Mitigated | All responses cite specific sources; confidence scoring |
| **ML Risk Model** | Disabled | Model AUC=0.51; using clinical hazard ratios instead |
| **Query Latency** | Acceptable | Caching with async warmup (15-min refresh) |
| **Token Limits** | Managed | Chunked document processing; max_output_tokens enforced |

### Data Constraints

- Both protocols from **ClinicalTrials.gov** (publicly available)
- TKA patient data is **synthetic** (no real PHI)
- Registry data from **public annual reports** only (AOANJRR, NJR, NCDR)
- Literature from **PubMed open access** subset

### What's NOT Implemented

| Feature | Status |
|---------|--------|
| Commercial/Sales data integration | Planned |
| Post-market surveillance (MDR, complaints) | Planned |
| Manufacturing/Quality data | Planned |
| Real-world evidence (claims, EHR) | Not implemented |
| Production validation (IQ/OQ/PQ) | Not completed |
| Multi-study support | Single study only |

---

## User Personas

> **PoC Feasibility Summary by Persona:**
> | Persona | Overall Feasibility | Demonstrable Prompts | Notes |
> |---------|---------------------|---------------------|-------|
> | Product Manager | ðŸŸ¡ **55%** | 4 of 7 | Safety/clinical yes, recall risk/regulatory docs limited |
> | Sales | ðŸŸ¡ **45%** | 3 of 7 | Literature rebuttals yes, CRM/surgeon data no |
> | Marketing | ðŸŸ¢ **65%** | 5 of 7 | SOTA/literature strong, congress abstracts limited |
> | Clinical Ops | ðŸŸ¡ **55%** | 4 of 7 | Protocol compliance yes, eTMF/financial limited |
> | Strategy | ðŸ”´ **25%** | 2 of 7 | Registry trends yes, VoC/sentiment no |
> | Quality Head | ðŸŸ  **30%** | 2 of 7 | Synthetic complaints possible, vigilance/RMF no |

### Persona 1: Product Manager (The "Product Guardian") ðŸŸ¡

**Objective:** Oversee product lifecycle health, safety signals, and clinical success to prevent recalls and maintain market leadership.

**PoC Feasibility: 55%** - Strong on clinical trial analytics and safety monitoring. Limited on recall risk (requires real complaint data) and regulatory document gaps (requires real eTMF).

**Primary Modules:**
- Safety Monitoring
- Executive Dashboard
- Regulatory Readiness
- Patient Risk
- Data Sources

**Core Use Cases:**
- **Safety Risk Monitoring**: Identifying early-warning signals in adverse events (AEs)
- **Clinical Performance Tracking**: Monitoring revision rates vs. industry benchmarks
- **Regulatory Compliance**: Tracking document completeness for MDR/FDA

**RBAC Policy:** Full safety data, registry access, regulatory documents, patient-level data for safety analysis

**Strategic AI Prompts:**

1. ðŸŸ¢ **Safety Correlation:** *"Analyze the study and identify if there is any statistical correlation between component size and the incidence of complications across all study sites."*

2. ðŸŸ¢ **Benchmark Analysis:** *"Compare the 2-year survivorship of our product (98.1%) against the bottom 25% of similar systems in the National Joint Registry."*

3. ðŸ”´ **Recall Risk Assessment:** *"Review the last 12 months of device deficiency reports. Is there a rising trend in specific mechanical failures that warrants a proactive field safety notice?"* *(Requires real complaint/deficiency data)*

4. ðŸŸ¢ **Demographic Impact:** *"Identify if revision rates are significantly higher in patients with a BMI over 35, and recommend if instructions for use (IFU) should be updated."*

5. ðŸ”´ **Regulatory Gap Analysis:** *"Check the document repository and list all required 'Clinical Evaluation Reports' (CER) that are missing or will expire within the next 6 months."* *(Requires real eTMF/document repository)*

6. ðŸŸ¢ **Site-Specific Performance:** *"Identify which clinical study sites have a revision rate that is >2 standard deviations away from the study mean, and list the common surgeons at those sites."*

7. ðŸŸ¢ **Data Synthesis:** *"Summarize all intraoperative complications reported in the study and categorize them by 'Device-Related' vs. 'Procedure-Related'."*

---

### Persona 2: Sales (The "Competitive Closer") ðŸŸ¡

**Objective:** Use real-world evidence and clinical data to defend market share and convert competitor surgeons.

**PoC Feasibility: 45%** - Literature-based competitive analysis strong. CRM/surgeon database integration not available for champion identification.

**Primary Modules:**
- Sales Intelligence
- Competitive Benchmarking
- Literature Intelligence
- Data Browser

**Core Use Cases:**
- **Competitive Battle Cards**: Instant evidence-based rebuttals
- **Economic Value Modeling**: Proving cost-savings via clinical superiority
- **HCP Relationship Management**: Identifying brand champions through data

**RBAC Policy:** Aggregated clinical data, competitive data, surgeon performance metrics, no patient-level data

**Strategic AI Prompts:**

1. ðŸŸ¢ **The Rebuttal:** *"Draft a rebuttal for a surgeon currently using a competitor system, specifically highlighting our 88.5% success rate versus the 76.3% found in our control group."*

2. ðŸŸ¢ **Outcome Visualizer:** *"Extract the functional score improvements (from 43.9 to 92.9) and generate a summary showing mobility gains for sedentary patients."*

3. ðŸŸ¢ **Competitor Weakness:** *"Search recent literature for known complications of 'Competitive Product X' and cross-reference them with our study to show how our product avoids those issues."*

4. ðŸŸ¡ **Procurement Pitch:** *"Calculate the predicted 5-year revision cost savings for a hospital if they switch from a competitor with a 94% survival rate to our observed 100% survival."* *(Survival data available; hospital-specific economics limited)*

5. ðŸŸ¢ **Technical Deep-Dive:** *"Provide a simple explanation of the material benefits in our liners compared to standard UHMWPE for a surgeon who is concerned about long-term wear."*

6. ðŸ”´ **Champion Identification:** *"Based on recent registry data, identify surgeons in the Northeast region who are publishing high-success rates using our implants."* *(Requires CRM/surgeon database)*

7. ðŸ”´ **Sales Scripting:** *"Generate a 30-second elevator pitch for our stemless system based on the anatomical restoration data found in our internal white papers."* *(Requires internal white papers)*

---

### Persona 3: Marketing (The "Brand Storyteller") ðŸŸ¢

**Objective:** Translate complex clinical data into compelling market claims and "State-of-the-Art" content.

**PoC Feasibility: 65%** - Literature synthesis and SOTA generation are strong. Congress abstracts (copyrighted competitor content) and internal CSRs limited.

**Primary Modules:**
- Literature Intelligence
- Document Generation
- Content Studio
- Competitive Benchmarking

**Core Use Cases:**
- **State-of-the-Art (SOTA) Reporting**: Automated synthesis of market trends
- **Claim Validation**: Ensuring all marketing copy is clinically supported
- **Patient Education**: Simplifying clinical outcomes for patient-facing content

**RBAC Policy:** Published data, evidence summaries, aggregated outcomes, no raw patient data or PII

**Strategic AI Prompts:**

1. ðŸŸ¢ **SOTA Generation:** *"Generate a comprehensive 'State-of-the-Art' report for stemless arthroplasty using internal CSRs and the last 3 years of PubMed publications."*

2. ðŸŸ¢ **Claim Validator:** *"Check if the claim 'Industry-leading safety' is supported by the AE rates in our study compared to three major competitors."*

3. ðŸŸ¢ **Patient Success Narrative:** *"Identify 'super-responder' patients in the study (those with >50 point functional score improvement) and draft a de-identified patient success story for our website."*

4. ðŸŸ¢ **Visual Data Extraction:** *"Create a table comparing the responder rates (89.8%) from our latest study against the industry average for similar procedures."*

5. ðŸ”´ **Congress Intelligence:** *"Scan competitor abstracts from the latest major meeting and identify the top three themes being used to market competitive products."* *(Requires copyrighted congress abstracts - cannot synthesize)*

6. ðŸŸ¢ **Channel Optimization:** *"Draft a series of LinkedIn posts targeting orthopedic surgeons that highlight the 0% device-related adverse events in our study."*

7. ðŸŸ¡ **Brand Perception:** *"Analyze the language used in recent Clinical Investigation Reports to identify the most frequently used positive adjectives to describe our system."* *(Limited to available synthetic CSR data)*

---

### Persona 4: Clinical Operations (The "Compliance & Financial Lead") ðŸŸ¡

**Objective:** Manage the execution, data integrity, and complex financials of global clinical studies.

**PoC Feasibility: 55%** - Protocol compliance and deviation monitoring strong with synthetic data. Financial systems and eTMF require enterprise integration.

**Primary Modules:**
- Financial Dashboard
- Protocol Deviations
- Protocol Digitization
- Data Browser

**Core Use Cases:**
- **Financial Tracking**: Monitoring CRO costs, site payments, and budget forecasts
- **Study Oversight**: Enrollment tracking and protocol deviation monitoring
- **GCP Compliance**: Ensuring eTMF and ISF completeness

**RBAC Policy:** Full study data, financial data, compliance documents, patient-level data for data management

**Strategic AI Prompts:**

1. ðŸŸ  **Financial Forecast:** *"Analyze the current CRO change orders and provide a budget estimate for the remaining 24 months of the 5-year follow-up period."* *(Can demo with synthetic financials; limited business value)*

2. ðŸŸ  **Automated Site Payments:** *"Calculate the total site payments due for Q4 by cross-referencing completed eCRF visits with the per-patient fee schedule in the site contracts."* *(Can demo workflow; requires real contracts)*

3. ðŸŸ¢ **Site Risk Alert:** *"Identify study sites that have an enrollment rate <50% of their target but have consumed >80% of their allocated budget."*

4. ðŸŸ¢ **MedDRA Coding Check:** *"Scan the 'Other' category in our AE reports and suggest the correct MedDRA coding for entries that mention 'persistent joint discomfort'."*

5. ðŸ”´ **Document Audit:** *"Review the electronic Trial Master File (eTMF) and flag any sites where the Principal Investigator's medical license has expired."* *(Requires real eTMF - cannot synthesize)*

6. ðŸŸ¢ **Missing Data Analysis:** *"Identify sites with a >20% rate of 'Lost to Follow-up' and analyze if there is a correlation between patient age and study withdrawal."*

7. ðŸŸ¢ **Protocol Compliance:** *"Search for all reported protocol deviations related to 'post-operative imaging window' and identify which sites require additional training."*

---

### Persona 5: Strategy (The "Visionary") ðŸ”´

**Objective:** Refine the product portfolio, monitor user sentiment, and identify long-term market opportunities.

**PoC Feasibility: 25%** - Most strategy prompts require VoC/sentiment data (real human feedback). Registry survivorship trends are demonstrable with public data.

**Primary Modules:**
- Portfolio Health
- Simulation Studio
- Competitive Benchmarking
- Data Browser

**Core Use Cases:**
- **Portfolio Health & Sentiment**: Analyzing the "Voice of the Customer" from registries and surveys
- **Product Refinement Strategy**: Identifying gaps in current designs based on clinical feedback
- **Macro-Trend Analysis**: Monitoring the impact of regulatory changes and market shifts

**RBAC Policy:** Cross-portfolio data, market trends, aggregated feedback, surgeon CRM data for market analysis

**Strategic AI Prompts:**

1. ðŸ”´ **Sentiment Gap Analysis:** *"Analyze surgeon feedback from Investigator-Initiated Studies (IIS) and identify the top 3 requested refinements for the next generation of our product."* *(Requires real IIS/surgeon feedback - synthetic opinions are meaningless)*

2. ðŸŸ¢ **Portfolio Sustainability:** *"Compare 10-year survivorship trends of our cemented vs. uncemented portfolios. Should we shift R&D focus based on the aging demographic trends in the EU?"*

3. ðŸ”´ **Voice of Customer (VoC):** *"Perform a sentiment analysis on the last 100 internal surveys regarding our instrumentation. Is the feedback on 'ease of use' improving or declining compared to 2022?"* *(Requires real survey data - cannot synthesize sentiment)*

4. ðŸŸ¡ **Competitive Threat Assessment:** *"Evaluate the risk of new 'robotics-assisted' systems on our current manual portfolio based on clinical success trends in registry data."* *(Registry trends available; market data limited)*

5. ðŸŸ¢ **Refinement Opportunity:** *"Examine the fracture rate in our study. Based on patient bone-density data, should we develop a 'reinforced' version for high-risk osteoporotic patients?"*

6. ðŸ”´ **Global Market Entry:** *"Simulate the clinical evidence requirements needed to launch our portfolio in the Japanese market based on recent PMDA regulatory shifts."* *(Requires regulatory intelligence feeds)*

7. ðŸ”´ **Interdisciplinary Advice:** *"Based on all clinical and sales data, recommend whether we should pursue a 'value-segment' product or continue focusing on 'premium-tech' revisions."* *(Requires real sales data)*

---

### Persona 6: Quality Head ðŸŸ 

**Mission:** To ensure zero-defect manufacturing, proactive risk mitigation, and a state of "perpetual audit readiness." This persona owns the feedback loop between real-world complaints and internal process improvements.

**PoC Feasibility: 30%** - Can demonstrate workflow with synthetic complaints/CAPA data. However, vigilance reporting, RMF updates, and manufacturing correlation require real enterprise data that cannot be meaningfully synthesized.

**Primary Modules:**
- Complaints Hub
- CAPA Dashboard
- Safety Monitoring
- Data Sources

**Specialized Module Features (Quality-Specific):**
- **Complaints Management Hub**: AI-driven triage center that categorizes incoming reports, detects trending failure modes, and automates Medical Device Reporting (MDR/Vigilance) decisions
- **CAPA & Vigilance Dashboard**: Real-time tracking of Corrective and Preventive Actions (CAPAs), linking them directly to the clinical or manufacturing data that triggered them
- **Risk Management File (RMF) Live Link**: Automatically flags when a "Real-World" complaint or adverse event exceeds the predicted "Risk Occurrence" levels defined in the product's technical file
- **Post-Market Surveillance (PMS) Analytics**: Correlates complaint data with sales volumes to calculate "Complaints Per Million" (CPM) and identify geographic or batch-specific quality clusters

**Core Use Cases:**
- **Complaints Management**: AI-driven categorization and trend detection
- **CAPA & Vigilance**: Tracking corrective actions and regulatory reporting
- **Post-Market Surveillance Analytics**: CPM calculation and cluster identification

**RBAC Policy:** All quality data, manufacturing data, complaint records, patient-level data for vigilance reporting

**Strategic AI Prompts:**

1. ðŸ”´ **Trend Detection vs. Sales Volume:** *"Analyze the complaint rate over the last 18 months. Normalize the data against sales volume (CPM) and identify if the 5% increase in 'liner wear' reports is statistically significant or a byproduct of market growth."* *(Requires real complaints + sales volume data)*

2. ðŸ”´ **Root Cause Cross-Analysis:** *"Cross-reference recent complaints regarding 'baseplate loosening' with manufacturing lot numbers and clean-room environmental logs. Is there a correlation between these events and the batch produced in Q3 2024 at a specific facility?"* *(Requires real manufacturing/environmental data - cannot synthesize sensor logs)*

3. ðŸŸ  **CAPA Effectiveness Check:** *"Review the effectiveness of CAPA-2023-004 (designed to address locking screw issues). Compare the incident rate in products manufactured before the fix versus those manufactured after the implementation."* *(Can demo workflow with synthetic CAPA; limited real value)*

4. ðŸ”´ **Vigilance Reporting Logic:** *"A surgeon reported a 'suspected' material failure during a revision surgery. Based on FDA 21 CFR 803 and EU MDR Article 87, determine if this event meets the 'Serious Deterioration of Health' threshold and draft the initial Vigilance report."* *(Vigilance reports are regulatory artifacts - cannot meaningfully synthesize)*

5. ðŸ”´ **Risk File Update:** *"Scan all post-market data. Identify any 'new' hazardous situations reported by surgeons that are not currently listed in the existing Risk Management File (RMF) for this device class."* *(Requires real RMF and post-market data)*

6. ðŸ”´ **Silent Quality Signal Search:** *"Perform a sentiment analysis on the last 100 entries in the 'Service & Repair' logs. Are there recurring technician comments regarding 'instrument stiffness' that have not yet been escalated to a formal complaint?"* *(Requires real technician notes - synthetic comments are meaningless)*

7. ðŸŸ  **Supplier Quality Audit Preparation:** *"Generate a 'Quality Scorecard' for our primary material supplier by aggregating all material-related complaints, incoming inspection failures, and clinical study deviations from the last 24 months."* *(Can demo workflow with synthetic data; limited real value)*

---

## API Endpoints

### Use Case Endpoints (UC1-UC8)

| Endpoint | Method | Purpose |
|----------|--------|---------|
| `/api/v1/uc1/readiness-assessment` | GET | Regulatory readiness report |
| `/api/v1/uc2/safety-summary` | GET | Safety signal analysis |
| `/api/v1/uc3/deviations-summary` | GET | Deviation detection |
| `/api/v1/uc4/population-risk` | GET | Risk stratification |
| `/api/v1/uc5/executive-summary` | GET | Executive dashboard |
| `/api/v1/uc6/literature-search` | POST | Literature intelligence & evidence synthesis |
| `/api/v1/uc7/generate-document` | POST | Document generation (DSMB, narratives) |
| `/api/v1/uc8/competitive-analysis` | GET | Competitive benchmarking |

### Extended Use Case Endpoints (UC9-UC20)

| Endpoint | Method | Purpose | Primary Persona |
|----------|--------|---------|-----------------|
| `/api/v1/uc9/recall-risk` | POST | Recall risk assessment | Product Manager |
| `/api/v1/uc10/battle-card` | POST | Competitive battle cards | Sales |
| `/api/v1/uc11/economic-value` | POST | Economic value modeling | Sales |
| `/api/v1/uc12/sota-report` | POST | SOTA report generation | Marketing |
| `/api/v1/uc13/financial-forecast` | POST | Financial forecast | Clinical Ops |
| `/api/v1/uc14/etmf-audit` | GET | eTMF audit | Clinical Ops |
| `/api/v1/uc15/portfolio-health` | GET | Portfolio health analysis | Strategy |
| `/api/v1/uc16/sentiment-analysis` | POST | Sentiment analysis (VoC) | Strategy |
| `/api/v1/uc17/complaints-triage` | POST | Complaints triage | Quality |
| `/api/v1/uc18/capa-effectiveness` | GET | CAPA effectiveness | Quality |
| `/api/v1/uc19/vigilance-report` | POST | Vigilance reporting | Quality |
| `/api/v1/uc20/pms-analytics` | GET | PMS analytics (CPM) | Quality |

### Supporting Endpoints

| Endpoint | Method | Purpose |
|----------|--------|---------|
| `/api/v1/chat/chat` | POST | Natural language queries |
| `/api/v1/protocol/overview` | GET | Protocol metadata |
| `/api/v1/simulation/monte-carlo` | POST | Outcome simulation |
| `/api/v1/data-browser/tables` | GET | Available tables |
| `/health/ready` | GET | Health check |

### ML/DL Predictive Endpoints

| Endpoint | Method | Purpose | Tier |
|----------|--------|---------|------|
| `/api/v1/ml/enrollment-forecast` | POST | Enrollment projections with confidence intervals | 1 |
| `/api/v1/ml/survival-analysis` | POST | Survival curves and hazard ratios | 1 |
| `/api/v1/ml/safety-signals` | POST | Bayesian signal detection and alerts | 1 |
| `/api/v1/ml/risk-stratification` | POST | Enhanced risk scores with SHAP explanations | 1 |
| `/api/v1/ml/outcome-trajectory` | POST | Patient outcome trajectory predictions | 2 |
| `/api/v1/ml/deviation-risk` | POST | Protocol deviation probability scores | 2 |
| `/api/v1/ml/extract-safety-terms` | POST | LLM-based MedDRA term extraction from narratives | 3 |
| `/api/v1/ml/classify-evidence` | POST | LLM-based literature evidence classification | 3 |
| `/api/v1/ml/functional-recovery` | POST | Recovery phenotype classification and prediction | 3 |

---

## Deployment

### Current Environment

| Aspect | Configuration |
|--------|---------------|
| **Backend** | FastAPI with uvicorn |
| **Frontend** | React SPA (Vite build) |
| **Database** | PostgreSQL with pgvector extension |
| **Hosting** | Replit (development) |

### Production Considerations (Future)

- HIPAA compliance for real patient data
- 21 CFR Part 11 validation
- SSO integration
- Audit logging
- Load balancing

---

## Summary

The Clinical Intelligence Platform v0.1 delivers a **functional proof-of-concept** demonstrating capabilities across **two therapeutic areas** with a **Persona-Driven Agentic Architecture** supporting **six enterprise personas**.

### PoC Feasibility Summary

| Category | PoC Ready | Partial | Synthetic Possible | Future Vision |
|----------|:---------:|:-------:|:------------------:|:-------------:|
| **Dashboard Modules** | 12 | 2 | 3 | 1 |
| **Use Cases (UC1-UC20)** | 9 | 4 | 3 | 4 |
| **Strategic Prompts (42)** | 16 (38%) | 6 (14%) | 4 (10%) | 16 (38%) |
| **Enterprise Data Sources** | 0 | 2 | 4 | 4 |

**Key Insight**: The PoC demonstrates strong value for **clinical trial intelligence** (safety, compliance, literature, competitive analysis) but has limited coverage for **post-market/enterprise workflows** (Quality, Strategy personas) that require real organizational data.

### Capability Matrix by Persona

| Capability | PM | Sales | Mktg | ClinOps | Strategy | Quality |
|------------|:--:|:-----:|:----:|:-------:|:--------:|:-------:|
| Safety signal detection | âœ… | â€” | â€” | âœ… | â€” | âœ… |
| Registry benchmarking | âœ… | âœ… | âœ… | â€” | âœ… | â€” |
| Competitive analysis | âœ… | âœ… | âœ… | â€” | âœ… | â€” |
| Literature intelligence | âœ… | âœ… | âœ… | â€” | âœ… | â€” |
| Document generation | âœ… | âœ… | âœ… | âœ… | â€” | âœ… |
| Risk stratification | âœ… | â€” | â€” | âœ… | â€” | âœ… |
| Financial tracking | â€” | â€” | â€” | âœ… | âœ… | â€” |
| Complaints management | âœ… | â€” | â€” | â€” | â€” | âœ… |
| CAPA tracking | â€” | â€” | â€” | â€” | â€” | âœ… |
| Sentiment analysis | â€” | â€” | â€” | â€” | âœ… | âœ… |
| Portfolio analysis | â€” | â€” | â€” | â€” | âœ… | â€” |
| Protocol compliance | âœ… | â€” | â€” | âœ… | â€” | â€” |

### Platform Summary

| Capability | TKA | DES | Status |
|------------|-----|-----|--------|
| Two-tier agent architecture (6 Persona + 12 Specialized) | âœ… | âœ… | Operational |
| Goal-based planning & orchestration | âœ… | âœ… | Operational |
| RBAC-controlled data access (6 personas) | âœ… | âœ… | Operational |
| Natural language clinical queries | âœ… | âœ… | Operational |
| Regulatory readiness assessment | âœ… | âœ… | Operational |
| Safety signal detection | âœ… | âœ… | Operational |
| Protocol deviation detection | âœ… | â€” | TKA Only |
| Patient risk stratification | âœ… | â€” | TKA Only |
| Registry benchmarking | âœ… | âœ… | Operational |
| Literature intelligence & evidence synthesis | âœ… | âœ… | Operational |
| Document generation (DSMB, narratives) | âœ… | âœ… | Operational |
| Competitive benchmarking | âœ… | âœ… | Operational |
| Monte Carlo simulation | âœ… | âœ… | Operational |
| Provenance tracking | âœ… | âœ… | Operational |
| Protocol digitization (USDM 4.0) | âœ… | âœ… | Operational |
| ML/DL Predictive Capabilities (9 models) | âœ… | âœ… | Planned |
| Extended Use Cases (UC9-UC20) | âœ… | âœ… | Planned |
| Enterprise Data Integration (PMS, CRM, eTMF, Financial) | âœ… | âœ… | Planned |

**Key Differentiators**:
- **Persona-Driven Architecture**: 6 Goal-based Persona Agents orchestrate 12 Specialized Agents with RBAC enforcement
- **Enterprise-Wide Coverage**: Supports Product Manager, Sales, Marketing, Clinical Ops, Strategy, and Quality personas
- **42 Strategic AI Prompts**: 7 pre-built prompts per persona demonstrating platform capabilities
- **Cross-Therapeutic Extensibility**: Same architecture supports orthopedics (TKA) and cardiovascular (DES) with configuration-only changes
- **Evidence-to-Document Pipeline**: Seamless flow from literature search to regulatory document generation
- **Advanced ML/DL Stack**: 9 predictive models across 3 tiers (foundation, advanced, LLM-powered NLP)
- **20 Use Cases**: Comprehensive coverage from regulatory readiness to vigilance reporting

---

*Document Version: 0.1.2*
*Full Scope: TKA + DES | 6 Personas | 19 Modules (1 Foundation + 18 Operational) | 6 Persona Agents + 13 Specialized Agents | 9 ML/DL Models | 20 Use Cases | 42 Strategic Prompts*

**PoC Demonstrable Scope:**
- *Data: Synthetic clinical trials + Public registries (AOANJRR/NJR/NCDR) + PubMed open-access literature*
- *Personas: 4 with high feasibility (PM 55%, Marketing 65%, Sales 45%, Clinical Ops 55%)*
- *Use Cases: UC1-UC8 fully demonstrable, UC10-UC12 partially*
- *Strategic Prompts: 16 fully demonstrable (38%), 6 partial (14%), 4 synthetic workflow (10%)*

**Future Vision (Requires Enterprise Data Integration):**
- *Personas: Strategy (25%), Quality (30%) - require VoC/PMS/manufacturing data*
- *Use Cases: UC9, UC13-UC14, UC16, UC19-UC20 require enterprise systems*
- *Strategic Prompts: 16 require enterprise data (38%)*

*Status: Proof-of-Concept with clear PoC vs Future Vision separation*
